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Objectives: To describe the health services utilization and prescription drugs use in South 
Carolina Medicaid enrollees with Chronic Obstructive Pulmonary Disease (COPD); to 
determine the comparative effectiveness of levalbuterol vs. albuterol in terms of 
healthcare resources utilization (primarily COPD-related hospitalizations and emergency 
department visits); and to estimate the value for money of levalbuterol for COPD, which 
is a new treatment comparing to albuterol, using cost-consequence approach. 
 
Methods: A retrospective, observational, cohort (longitudinal) study of COPD patients in 
South Carolina Medicaid programs. The study identified patients with COPD and those 
who used albuterol and/or levalbuterol from 1999 to 2010. Descriptive statistics was used 
for health services and drugs use as well as patient profiles. Propensity score matching 
was used to control for selection bias in albuterol and levalbuterol users. Negative 
binomial regression was then employed to compare the number of healthcare resources 
utilization while offset follow-up period. A cost-consequence analysis was also conducted 
to compare the economic impact of initial use of levalbuterol and racemic albuterol on 
the subsequent healthcare costs. Cost data were adjusted to 2010 US$ value. 
 
Results: In total, 90,217 COPD patients were identified, and ~50% had ever at least one 
 ii 
prescription claim for either albuterol or levalbuterol. Using propensity score matching, 
343 pairs of COPD patients taking albuterol and levalbuterol were identified. There was 
no difference in health services utilization between these two groups. The conclusion is 
robust across most of the primary and secondary outcome measures and sensitivity 
analyses, except that levalbuterol users had 34% more COPD-related all healthcare 
resource utilization than albuterol users when regression model was done in all eligible 
patients rather than PS matched patients. The cost-consequence analysis showed that 
there was no difference in all-cause total healthcare costs between levalbuterol and 
racemic albuterol; however, the SC Medicaid programs paid for racemic albuterol users 
US$2775.6 less than for patients initially prescribed levalbuterol in the first year. 
 
Conclusions: Patients initially prescribed levalbuterol seemed to have no difference in 
all-cause health service utilization and healthcare cost in the following one year 
comparing with racemic albuterol, and there was significant difference in COPD-related 
health service use and costs. This suggests that racemic albuterol might be equally or 
similarly effective initial therapy for patients with COPD comparing with levalbuterol in 
the first year of their use. Future research is needed to examine the longer-term 
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CHAPTER 1: INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is a group of diseases of the 
airways characterized by airflow limitation that is not fully reversible and progressive 
loss of lung function, including emphysema, chronic bronchitis, and in some cases 
asthma.1-3 COPD is the fourth leading cause of death and 1 of the 10 leading causes of 
hospitalization in the United States.3,4 COPD is preventable and treatable. Effective, 
evidence-based medication therapy is a mainstay of COPD management to improve 
health outcomes, such as relief of symptoms and reduction in exacerbation frequency, 
exacerbation severity, hospitalization, days lost from work, and mortality.3,5 To 
standardize the care of patients with COPD, the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD, http://www.goldcopd.org/) was launched in 2001. The American 
Thoracic Society and the European Respiratory Society have also developed step therapy 
guidelines for COPD which are generally consistent with the GOLD recommendations 
(Table 1 & Figure 1).3,6 Based on these two guidelines, we could elicit the disease 
severity (Table 2) from the drug regimens which can usually be obtained from claims 




Table 1. Therapy at Each Stage of Chronic Obstructive Pulmonary Disease.* 
Stage I: Mild II: Moderate III: Severe IV: Very severe 
Diagnosis FEV1/FVC < 
0.70 








30% ≤ FEV1 < 
50% predicted 
FEV1/FVC < 0.70 
FEV1 < 30% predicted 
or FEV1 < 50% 
predicted plus chronic 
respiratory failure 
Intervention Active reduction of risk factor(s); influenza vaccination 
 Add short-acting bronchodilator (when needed) 
  Add regular treatment with one or more long-acting 
bronchodilators (when needed); Add rehabilitation 
   Add inhaled glucocorticosteroids if 
repeated exacerbations 





FEV1 = forced expiratory volume in one second; FVC = forced vital capacity. 
* Adapted by the author from the Global Strategy for Diagnosis, Management and 





Figure 1. Step Therapy for Patients with Chronic Obstructive Pulmonary Disease 
from the American Thoracic Society/European Respiratory Society guidelines.6 
PRN = pro re nata (as needed); QID = quarter in die (four times a day). 
 
Medication Therapy for Chronic Obstructive Pulmonary Disease (COPD) 
Medication therapy for COPD focuses on the use of bronchodilators to control 
symptoms. Bronchodilators include short-acting and long-acting β2- agonists (SABAs 
and LABAs, respectively), short-acting and long-acting anticholinergics, and 
methylxanthines including theophylline and aminophylline. Short-acting bronchodilators, 
including SABAs, short-acting anticholinergics such as ipratropium, and a combination 
of albuterol and ipratropium, are commonly used in patients with COPD at each stage for 
the treatment of intermittent symptoms, for rescue treatment of breakthrough symptoms 
in patients taking long-acting medications, or for maintenance therapy.1,3,6 Although there 
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are no recommendations for initial use of one bronchodilator over another,3,6 controversy 
persists regarding the comparative effectiveness (or comparative efficacy) of albuterol 
and levalbuterol in COPD (and asthma).3,7-11 
 
Albuterol and Levalbuterol 
In the medication therapy management of COPD, SABAs such as albuterol 
(called salbutamol outside the United States12) and levalbuterol are among the most 
commonly prescribed drugs. Racemic albuterol is a 1:1 mixture of (R)- and (S)-albuterol 
(Figure 2), with the (R)-isomer (i.e., levalbuterol) predominantly responsible for the 
therapeutic bronchodilator effect.13 Levalbuterol claims clinical superiority based on the 
absence of the (S)-isomer, which may worsen airway inflammation and antagonize the 
effect of (R)-albuterol. However, the advantages of using levalbuterol in clinical practice 
are not clear and require further investigation and more evidence,3 because studies 
reported conflicting results on the efficacy/effectiveness of these two drugs, and for 




Figure 2. Surface Topography Structures of Albuterol Isomers.9 
 
A randomized controlled trial (RCT) compared nebulized levalbuterol to racemic 
albuterol, ipratropium plus albuterol, and placebo in 30 patients with stable COPD. There 
were no significant differences in pulmonary function [forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC)] improvements or adverse effects (hand 
tremor) between nebulized levalbuterol and conventional bronchodilators.13 Donohue et 
al. reported two RCTs and found some advantages of levalbuterol as evidenced by 
reduction in rescue nebulization use compared with racemic albuterol.10,14 A retrospective 
chart review concluded that levalbuterol offered significant advantages over albuterol (for 
example, hospitalized patients with COPD or asthma treated with levalbuterol required 
less medication and had shorter length of stay, compared with those treated with racemic 
albuterol) and suggested levalbuterol as first-line therapy for patients hospitalized with 
COPD or asthma.15 However, some argue that the evidence to support levalbuterol use is 
not adequate and that its use is not justified due to the nebulized levalbuterol’s 5 times 
higher acquisition cost than nebulized albuterol; and thus the use of levalbuterol in 
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clinical practice requires further investigation.3,8,11 
It is reported that in 2006 there were 5.5 times more albuterol users than 
levalbuterol users among Medicare beneficiaries with COPD enrolled in part D. However, 
mean annual spending on levalbuterol was 18.6 times higher per user than albuterol, 
resulting in total spending by Medicare, secondary payers, and beneficiaries on 
levalbuterol of ~$169 million while on albuterol of ~$50 million.16 In the era of 
comparative effectiveness research (CER)17 and value-based medicine pricing and 
purchasing, there is a need to further investigate the clinical effectiveness and cost benefit 
of albuterol and levalbuterol in real-world clinical practice. 
 
Significance of the Study 
This study would have a positive impact because it provides healthcare 
policymakers, prescribers, and even patients with the comparative-effectiveness and 
cost-consequence profiles of albuterol and levalbuterol to help determine which 
alternative would have clinical advantages and be more cost beneficial for the 
management of COPD. By providing observational evidence on this issue, further 
follow-up evaluations might be provoked even though the results of this study are not 




This study was conducted to describe healthcare resource utilization and drug use, 
and compare the clinical effectiveness and cost benefit of albuterol and levalbuterol for 
the treatment of COPD in South Carolina (SC) Medicaid enrollees from 1999 to 2010, 
using SC Medicaid databases provided by the Office of Research and Statistics (ORS), 
SC Department of Health and Human Services (DHHS).  
The specific study objectives are as follows: 
Objective 1: To describe healthcare resource utilization, prescription drug use, 
and corresponding expenditures on COPD, and overall characteristics of COPD patients. 
Objective 2: To compare the clinical effectiveness of albuterol and levalbuterol in 
patients with COPD, mainly in terms of hospitalizations and emergency department (ED) 
visits.18 
Objective 3: To evaluate the cost consequence of albuterol and levalbuterol in the 
management of COPD from the payer (i.e., SC Medicaid program) perspective. 
 
Research Questions/Hypotheses 
Question for objective 1: What are the profiles of drug use, healthcare resource 
utilization, and spending in SC Medicaid health maintenance organization (HMO) and 
fee-for-service (FFS) beneficiaries with COPD? 
Null hypothesis for objective 2: There is no significant difference in the numbers 
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of hospitalizations and ED visits within a specified time period between COPD patients 
receiving albuterol and levalbuterol. 
Questions for objective 3: Which alternative, albuterol or levalbuterol, is more 




CHAPTER 2: LITERATURE REVIEW 
 
COPD Epidemiology in the United States 
Chronic obstructive pulmonary disease (COPD) is a group of diseases of the 
airways characterized by airflow limitation that is not fully reversible and progressive 
loss of lung function, including emphysema, chronic bronchitis, and in some cases 
asthma.1-3  
It is estimated that 12.7 million (age-adjusted prevalence 5.5%) adults aged 18 
years and older in the United States had been diagnosed with COPD according to the 
2011 National Health Interview Survey (NHIS); this number is underestimated compared 
to 14.7 million (6.2%) from the 2011 Behavioral Risk Factor Surveillance System 
(BRFSS).19 The prevalence varied considerably by state, from <4% in Washington and 
Minnesota to >9% in Alabama and Kentucky.20 
COPD was the third (once fourth3,4) leading cause of death (claiming the lives of 
134,676 Americans in 2010) and the 12th leading cause of morbidity in the U.S.21,22 
COPD is also 1 of the 10 leading causes of hospitalization in the United States. The 
age-standardized death rates (per 100,000 U.S. population) for COPD in the U.S. ranged 
from 39.5 to 43.4 in 1999–2010. The death rate in 2010 was 40.8 per 100,000. Male death 
rate for COPD was higher than female. In 2010, age-standardized death rates in male was 
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47.6 per 100,000 U.S. population while in female 36.4 per 100,000.20 
In South Carolina (SC), the age-adjusted prevalence of COPD was 7.1% in 
2011.23 As for the prevalence in SC Medicaid population, it was reported that in 2010, a 
total of 47,321 Medicaid recipients had paid claims associated with a primary diagnosis 
of COPD or 5.01% of the total Medicaid recipient population.24 It seemed that the 
prevalence of COPD in SC Medicaid population was lower than that in SC general 
population (not statistically tested correct and the definitions of COPD might not be the 
same). 
 
Economic Burden of COPD in the U.S. as well as in the Medicaid Populations 
Due to the high prevalence of COPD and its comorbidities and/or complications, 
the economic burden of this disease is heavy. In 2010, the cost of COPD in the U.S. was 
projected to be approximately $49.9 billion, including $29.5 billion (~60%) in direct 
health care expenditures, $8.0 billion in indirect costs due to lost productivity caused by 
COPD, and $12.4 billion in indirect mortality costs resulting from productivity lost due to 
premature death.24,25 In the SC Medicaid programs, the total medical expenditures for 
COPD patients were $475.7 million, accounting for 9.2% of the state Medicaid 
expenditures in 2010.24 Taking the prevalence (7.1% in SC general population in 2011 
and 5% in SC Medicaid population in 2010, see above) into account, COPD is a 
relatively expensive disease (fewer people spend more money). 
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In particular, a few studies examined the economic burden of COPD26 (including 
concomitant COPD and asthma,27,28 and COPD’s comorbidities29) in the U.S. Medicaid 
populations. D’Souza et al.26 evaluated the clinical and economic burden of COPD 
patients to Medicaid (incremental costs incurred and medical resources used by COPD 
patients relative to those without COPD) using Medicaid claims data of 8 states during 
2003–2007. The study found that inpatient hospitalizations were one of the primary 
drivers of incremental medical costs. COPD patients were more than twice as likely to 
have a hospitalization (odds ratio [95% confidence interval] = 2.32 [2.19, 2.45]) 
compared to non-COPD patients. Medicaid incurred $2118/year in incremental costs due 
to COPD. They concluded that COPD imposed a substantial economic burden on the 
Medicaid program. Lin et al.29 used Maryland Medicaid managed care claims data to 
explore the economic implications of comorbidity among patients with COPD compared 
to demographically matched non-COPD controls with similar age, sex, and race. 
Medicaid COPD patients had higher comorbidity burden and were more likely to have 
myocardial infarction, congestive heart failure, cerebrovascular disease, hypertension, 
and tobacco use etc. On average, COPD patients had 24% more medical claims (81.4 vs. 
65.4, p < 0.001) and were 33% more expensive than non-COPD controls ($7603 vs. 
$5732, difference $1871, p < 0.001). 
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Risk Factors for and Comorbidities of COPD 
Factors influencing health service utilization and economic burden of COPD 
include risk factors for and comorbidities (or coexisting medical conditions) of this 
disease, except COPD itself.5,29 Important risk factors include tobacco smoking, aging, 
exposure to particles, socioeconomic status, asthma/bronchial hyperreactivity, chronic 
bronchitis, infections, and genes.1,30 Comorbidities include cardiovascular diseases 
(including ischemic heart disease, heart failure, atrial fibrillation, and hypertension), 
osteoporosis, anxiety and depression, malignancies such as lung cancer, infections, 
diabetes, metabolic syndrome, bronchiectasis, and musculoskeletal disorders.1,30,31 These 
are all important variables required to be considered in this study. 
 
Medications for Management of COPD 
In addition to 1) identification and reduction of exposure to risk factors and 2) 
non-pharmacologic treatments, effective medication therapy is a mainstay of COPD 
management. The medications for the management of COPD are shown in Table 2 and 
Table 3 below. As shown in Table 2, the disease management guidelines provide 
differing medication therapies for mild to very severe COPD. When clinical practices 
comply with the COPD treatment guidelines, we may be able to examine a COPD 
patient’s disease stage in terms of the medications prescribed. For example, for a COPD 
patient who receives short-acting bronchodilators only, we may infer this patient’s COPD 
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is mild. When a COPD patient is prescribed corticosteroids in addition to short- and 
long-acting bronchodilators, he/she may have severe to very severe COPD. The inference 
is important when claims database is available for use to compare COPD patients and 
their health outcomes, because generally there is no specific disease stage information in 
the claims database. Based on this assumption, we could examine a patient’s medication 
use history and determine his/her COPD severity, which is an important predictor of 
health outcomes measured (such as health services utilization after baseline date). 
 
Albuterol and Levalbuterol for COPD 
Table 3 lists the drug classes and specific medications frequently used by COPD 
patients, according to guidelines and literatures.1,3,6,16,30 SABAs are therapies at first step 
of COPD management (see Figure 1) and one of the most commonly prescribed drug 
classes as mentioned in Chapter 1, although long-acting formulations (including both 
beta2-agonists and anticholinergics
1) are preferred over short-acting ones when both are 
indicatable.1,30 The research of comparative effectiveness of racemic albuterol and 
levalbuterol for the management of COPD is limited (only 18 results retrieved on March 
13, 2015 on PubMed website: 
http://www.ncbi.nlm.nih.gov/pubmed/?term=albuterol+levalbuterol+COPD) and the 
results of published studies are conflicting and thus controversial (see Chapter 1).3 The 
benefit-to-cost ratio of levalbuterol over albuterol is also required to be examined further 
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(see Cost-Consequence Analysis below). These are two primary study objectives of this 
dissertation research. 
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Table 2. Severity of Chronic Obstructive Pulmonary Disease Based on the Medication Therapy Management from the Global 
Initiative for Chronic Obstructive Lung Disease1 and the American Thoracic Society/European Respiratory Society Guidelines6 
Severity Short-acting bronchodilator 
(β2- agonist, anticholinergic, 
and combination) 
Long-acting bronchodilator 








Mild Yes    
Moderate Yes Yes   
Severe to 
very severe 
Yes Yes Yes Yes/No 
 
Table 3. Medication Therapies for Chronic Obstructive Pulmonary Disease.1,3,6,16 
Class Drug 
Short-acting β2- agonist (SABA) albuterol, levalbuterol, (fenoterol
*,) terbutaline, pirbuterol, metaproterenol, bitolterol, 
isoetharine, and isoproterenol 
Short-acting anticholinergic ipratropium (and oxitropium*) 
Short-acting combination 
bronchodilator 
albuterol-ipratropium (and fenoterol-ipratropium*) 
Long-acting β2- agonist (LABA) salmeterol, formoterol, (indacaterol
†, tulobuterol*,) and arformoterol 
Long-acting anticholinergic tiotropium 
Methylxanthine theophylline, aminophylline, dyphylline, and oxtriphylline 
Inhaled corticosteroid‡ beclometasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, and 
triamcinolone 
Systemic corticosteroid‡ budesonide, methylprednisolone, prednisone, prednisolone, and triamcinolone 
LABA-steroid combination drug fluticasone-salmeterol, and budesonide-formoterol 
(Phosphodiesterase-4 inhibitor†) (roflumilast†) 
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Mast-cell stabilizer‡ cromolyn and nedocromil 
Leukotriene-receptor antagonist montelukast, zafirlukast, and zileuton 
Alpha-1 antitrypsin augmentation 
therapy32 
Prolastin-C®, Aralast NP™, Zemaira®(, and Glassia®†) 
* Fenoterol and its combination, oxitropium, and tulobuterol were not found in Red Book, South Carolina (SC) Medicaid databases, or 
Drugs@FDA website. 
† Indacaterol maleate (Arcapta Neohaler by Novartis) was approved by FDA on July 1, 2011 and roflumilast (Daliresp by Forest Res 
Inst Inc) was approved on February 28, 2011. Therefore, these two drugs are beyond the study period. 
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm) 
Glassia® (Baxter Healthcare) was approved in October 2010. It was not located in the database. 
‡ Steroids used topically on the eye, ear, nose, throat (EENT), skin, and mucous membrane (dosage form usually cream, lotion, 
ointment, paste, eye drop, and nasal spray [nasal aerosol]) were excluded according to information on drug name and National Drug 
Code (NDC) number identified from Red Book, SC Medicaid pharmacy claim databases, FDA CDER Databases (Drugs@FDA), and 
FDA NDC Directory. Also excluded was powder form for compounding purpose.  
However, the exclusion or inclusion here of dosage form and route of administration might not be accurate. This would lead to 
overestimate or underestimate systemic corticosteroids utilization to some extent. But the result of orally inhaled (nasal spray excluded) 




Comparative Effectiveness Research (CER) 
The CER is “the generation and synthesis of evidence that compares the benefits 
and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical 
condition or to improve the delivery of care. The purpose of CER is to assist consumers, 
clinicians, purchasers, and policymakers to make informed decisions that will improve 
health care at both the individual and population levels.”33 Observational studies help 
CER, filling the information gaps created by lack of evidence from randomized 
controlled trials (RCTs).34,35 
Observational studies include cross-sectional, cohort, and case-control designs. 
They can be prospective or retrospective, longitudinal or cross-sectional. The sources of 
data for observational studies are often secondary (vs primary), when the information/ 
data was not collected for the purpose of the research question itself, such as claims 
database.34 Other sources of data facilitating CER include population-based registry 
data35 and electronic health records (EHRs)36 [or referred to as electronic medical records 
(EMRs). Differences exist between EHR and EMR]. These data are usually real-world 
data which health economists/ pharmacoeconomists and outcomes researchers have been 
analyzing for decades; but today it is more commonly called Big Data. The importance of 
and approaches to observational studies, as well as its comparison to RCTs (advantages 
and disadvantages), are available elsewhere.34,35,37,38 In particular, the Agency for 
Healthcare Research and Quality (AHRQ) publishes a monograph entitled “Developing a 
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Protocol for Observational Comparative Effectiveness Research: A User’s Guide”38 
which is worth reading. In short, a well-designed and appropriately-analyzed 
observational study using big real-world data is useful for CER. 
However, one of the challenges in doing an observational study is how to properly 
control for the confounding factors arising from the lack of randomization process.34 
 
Propensity-Score Matching (PSM) 
Appropriate analytic techniques can control for confounders effectively, such as 
various multiple regression including logistic regression, Poisson regression, and Cox 
proportional hazard model, depending on the level of measurement of dependent 
variables and if the dependent/ outcome variables time-varying or not [see page 137 (or 
pdf file page 149 out of 208) of the AHRQ report38]. Another effective and often 
employed approach is propensity scores (PS) to controlling for confounding factors and 
to reducing selection bias. 
“Propensity scores are the probability of receiving treatment given the set of 
observed covariates. The probability of treatment is estimated conditional on a set of 
covariates and the predicted probability is then used as a balancing score or matching 
variable across treatment groups to estimate the treatment effect.”38 Propensity score 
matching (PSM) refers to the pairing of treatment (or case) and control subjects/ patients 
with similar values on the propensity score, and possibly other covariates, and the 
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discarding of all unmatched subjects. The goal of matching is to obtain similar groups of 
treated (treatment, or case) and untreated (control) by matching individual observations 
on their propensity scores. 
PSM generally follows the steps as below: 
1) Estimate propensity scores (i.e., calculate the probability of receiving a certain 
treatment). 
2) Match treatment and control subjects using propensity score methods to 
remove the effects of confounding when estimating the effects of treatment on 
outcomes.  
The PS methods commonly used include matching (1:1, 1:k, full), stratification or 
subclassification, inverse probability of treatment weights (IPTW), and propensity score 
weighting [other methods include ANCOVA (analysis of covariance) including 
propensity score as a covariate, and ANCOVA without PS].39,40 
The PSM is one of the PS methods. The most common implementation of 
propensity score matching is one-to-one or pair matching, which forms pairs of treated 
and control (or untreated) subjects who have similar values of the propensity score. 
Nearest neighbor (NN) matching selects an untreated subject for each treated unit based 
on the smallest distance from that treated subject in PS, with or without replacement (i.e., 
subjects are not returned to the sample or the matching process after being 
pair-matched).39,40 
3) Assess the PS balance, i.e., compare the similarity of treated and untreated 
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subjects in the matched sample. 
The standardized difference (usually < 0.1 [10%] indicating a negligible 
difference in the mean or prevalence of a covariate between treatment groups) can be 
used to compare the mean of continuous and binary variables between treatment groups.40 
In ideal circumstances, after PSM the two groups would be very similar on all 
covariates.39 
4) Estimate treatment effect after PSM and evaluation.  
“Once a matched sample has been formed, the treatment effect can be estimated 
by directly comparing outcomes between treated and untreated subjects in the matched 
sample.”40 However, when there are time-dependent outcome variables such as number of 
health services utilization during follow-up period (time-varying), appropriate analytical 
techniques are still required (e.g., Cox regression model to include time-dependent 
factors). 
Propensity score matching, as well as other PS analysis methods such as 
stratification and IPTW, is useful for selecting similar subjects in treated and untreated 
groups and for the subsequent examination of treatment effects. In addition, “Propensity 
score matching, followed by regression adjustment on the matched sample, can often be a 
stronger approach for estimating causal effects than is regression on an unmatched 
sample.”41 But no methods are perfect. Propensity score might be used in combination 




Cost-Consequence Analysis (CCA) 
While the healthcare spending has been increasing dramatically for decades and 
putting pressure of cost containment on to payers, government and other payers are 
relying on economic evaluation to determine which drugs, diagnostics, devices, or 
services be paid and at what level (i.e., reimbursement percentage). The goal of health 
economics and pharmacoeconomics is to spend less and benefit more from the societal 
perspective while also have special needs populations covered (i.e., reducing to 
minimizing or even eliminating disparities). The purpose of economic evaluation is to 
examine the health services/ interventions utilization and allocate the healthcare resources 
efficiently and rationally. 
There are four common approaches to conducting pharmacoeconomics research: 
cost-minimization analysis (CMA), cost-benefit analysis (CBA), cost-effectiveness 
analysis (CEA), cost-utility analysis (CUA), and sometimes also including the fifth 
method, cost-of-illness (COI) study. Among these types, CUA, CEA, CBA, and even COI 
might be more frequently seen in the medical literatures than CMA; CMA may be the 
easiest because it assumes the outcomes examined are equal for different interventions 
being compared. The unique characteristic of CBA is that its outcome measurement is in 
dollar value while other approaches (i.e., CUA, CEA, and CMA) use non-monetary 
outcomes (usually quality-adjusted life year [QALY] and clinical outcomes). We can find 
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these methodologies in textbooks or literatures of pharmacoeconomics or health 
economics. To detail and compare these study types is beyond the scope of this 
dissertation research. 
Another approach, the sixth one, is cost-consequence analysis (CCA). A 
cost-consequence analysis “provides the most comprehensive presentation of information 
describing the value of a drug therapy or other healthcare intervention, and is also 
conceptually the simplest.”45 A cost-consequence analysis lists all the relevant resource 
use and costs, and health outcomes or consequences of the intervention. “A good 
cost-consequence analysis should include estimates of the new treatment’s impact on 
multiple disease outcomes and present them in a sufficiently disaggregated format to 
meet the needs of decision-makers perhaps having widely different perspectives.”45 And 
therefore, cost-consequence analysis enables decision-makers to select the components 
most relevant to their perspective and help with resource allocation decisions.45,46 
Moreover, claims database is useful for a cost-consequence analysis as it provides 
longitudinal outcomes and resource utilization information for the measure of 
consequences.45 The CCA is suitable for this study which examines the value of 
levalbuterol comparing to albuterol from payer’s (SC Medicaid) perspective. 
But for this study, there is another specific issue regarding the interventions being 
compared: What dosage form of albuterol and levalbuterol would this study compare? 
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Aerosol Drug Delivery 
Aerosolized drugs are most often used for COPD, including inhalers of 
β2-agonists, anticholinergics, and corticosteroids. “Based on efficacy and side effects 
inhaled bronchodilators are preferred over oral bronchodilators (Evidence A).”1,30 
Inhalers include three types: metered dose inhaler (MDI), dry powder inhaler (DPI), and 
nebulizer.47-49 According to a review article published in 200712 and personal 
communication with Dr. Patricia Wigle (one of Committee members), dry-powder 
albuterol inhalers were not available in the United States. DPIs do not use propellants. 
MDIs “use a propellant under pressure to generate a metered dose of an 
aerosol”.47 Chlorofluorocarbons (CFCs) were propellants previously used in MDIs. 
Following the ban on CFCs, CFC-containing inhalers were mandated to be withdrawn by 
the end of 2008, while hydrofluoroalkane (HFA) drugs phased in. Subsequently, people 
were concerned about the transition as the cost of HFA albuterol inhalers was two to three 
times as much as generic CFC products.12,50 And thus the HFA albuterol inhalers may not 
be much less expensive than HFA levalbuterol. On the other hand, the acquisition cost of 
nebulized levalbuterol was 5 times higher than nebulized albuterol.8,11  
As a result, when this study examines the cost consequence of albuterol and 
levalbuterol for the management of COPD, it is requisite to differentiate dosage forms 
and propellants of albuterol and levalbuterol and then compare them correctly. 
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Difference-in-Difference (DID) Analysis and DID Regression 
Among various analytic techniques for two-group, pre-post repeated measures 
design, repeated measures ANOVA or difference-in-difference technique is recommended, 
by using SAS MIXED procedure.51,52 DID is a statistical technique used in econometrics 
and quantitative sociology. When dealing with pre-post data for groups receiving 
intervention or not (control group, or receiving positive control), the 
difference-in-difference analysis measures the difference in the differences between the 
treatment and control group over time. And thus the DID approach can examine 
time-series changes while controlling for the change due to secular changes, by 
mimicking random assignment of treatment and control samples in observational data. 
DID is widely used in policy implementation research as well as health services 
research. For example, Moll et al. contrasted the changes (12 months before versus 12 
months after the index date) in healthcare utilization, costs, and COPD exacerbations of 
the roflumilast-treated group compared with non-roflumilast-treated group using DID 
analytic approach.53 The DID analysis can be univariate analysis and multiple regression 
(i.e., multiple independent or explanatory variables in the regression model). The 
univariate DID analysis compares the difference in the dependent (or outcome) variable 
between intervention and control groups. The DID regression model adjusts for any 
baseline differences between cohorts and validate the univariate analysis findings. 
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CHAPTER 3: METHODOLOGY 
 
Study Design 
This is a population-based, retrospective, observational cohort (longitudinal) 
study using the South Carolina Medicaid claims databases. 
 
Data Source 
Offered by the South Carolina (SC) Office of Research and Statistics (ORS), the 
1999–2010 (12 years) SC Medicaid claims databases of patients with Chronic 
Obstructive Pulmonary Disease (COPD) have information on enrollees in two healthcare 
plan types: Health Maintenance Organizations (a type of managed care program) and 
Fee-for-Service providers. (In SC, there are three Medicaid healthcare plan types; the 
third one is Medical Home Networks.) The databases consist of such data sets as 
demographics, health service claims, and prescription drug claims, including information 
on demographics (age, sex etc.), period of enrollment in Medicaid, socioeconomic status 
(such as percentage below applicable poverty line and educational level), physician office 
visit, hospital’s outpatient, emergency department (ED), and inpatient services, and 
prescription drugs. The databases use two unique person-level identifiers which is 
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consistent across all data sets and years. Consequently, this study was able to track 
individuals longitudinally across the study years. The SC Medicaid databases are 
compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA). 
The databases are de-identified so that researchers are unable to link anything to recipient 
ID, social security number, or any other external identifier such as the National Death 
Index and registries. All dates in the databases were encrypted in the same manner; so the 
order and timing of enrollment and services can be determined without knowing the real 
date. And hence, this study was exempt from the review of Institutional Review Board 
(IRB) of the University of Cincinnati (Institutional Review Board Approval Letter). 
 
Objective 1: Patient Characteristics, Healthcare Resource Utilization, Drug Use, and 
Healthcare and Drug Expenditures 
Inclusion and exclusion criteria 
All patients who were enrolled in the SC Medicaid programs of HMO and FFS 
with a diagnosis of COPD between January 1, 1999 and December 31, 2010 were 
included for this analysis, no matter how old they were or how long they were covered by 
Medicaid. The COPD diagnosis was identified using the following International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes: 
491.2x (obstructive chronic bronchitis), 492.xx (emphysema), and 496.xx (chronic 
airway obstruction, not elsewhere classified).54-57 However, for the analysis of patient 
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demographic characteristics, those without consistent information were excluded. For 
example, if a patient’s start date of enrollment was later than the end date, then the patient 
was not included in the description of demographics. 
 
Definition and categorization of patient demographics 
Table 4 shows the patient demographic and socioeconomic characteristics and 
values of each variable involved in the study Objective 1. 
 
Table 4. Variables and Values of Patient Demographic and Socioeconomic 
Characteristics. 
Variable Value Note 
Age A continuous variable Age of years at first diagnosis 
Age group  < 18 
 18–44 
 44–65 
 ≥ 65 
Groups of age at first diagnosis of 
chronic obstructive pulmonary 
disease 




 Black or African American 
 Hispanic or Latino, American 





 Minimum–Quartile 1 
 Quartile 1–median 
 Median–quartile 3 
 Quartile 3–maximum (poorest) 
Inferred from neighborhood income 
derived from zip codes and 
applicable poverty line 
Education  Less than high school 
 High school, Special education, 
& Vocational training 





Healthcare resource utilization 
Healthcare resource utilization data included the numbers of outpatient, physician 
office, and ED visits, and number of hospitalizations, and length of stay. Raw cumulative 
frequencies of hospitalizations, and ambulatory care and ED visits were calculated. 
When counting the number of ambulatory care visit, the category of “other 
ambulatory care visit” in the data set was not included because it usually included x-ray 
and laboratory test etc. and would probably be related to another outpatient or physician 
office visit, an ED visit, or a hospitalization. However, the health expenditures related to 
“other ambulatory visit” were calculated (see “Healthcare and drug expenditures” below). 
Also, if an ambulatory care visit coincided with a hospitalization the same day, then the 
ambulatory care visit was not counted; only one hospitalization was aggregated instead. 
In addition, because there were multiple ambulatory care visits in one day (e.g., physician 
office visit + outpatient service), only one visit per patient per service day was counted to 
avoid overestimating the healthcare resource use.59 Therefore, the priority would be 
counting hospitalization first, followed by ED visit, outpatient, and physician office visit. 
The analysis was divided into all-cause and COPD-related health service 
utilization. Healthcare resource utilization for all causes was considered so that the 
research did not miss the services used for COPD comorbidities and/or other health 
conditions. COPD-related hospitalization, ED visit, and ambulatory care visit were 
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secondary outcomes.59 And COPD-related health services use (and COPD-related 
healthcare costs hereinafter also) was defined as healthcare encounters (and costs) for 
which the primary or secondary diagnosis was COPD (491.2x, 492.xx, and 496.xx) at a 
healthcare encounter.59,60 Healthcare encounters were defined as ambulatory care or ED 
visits not associated with hospitalization, and hospitalizations.60 
 
COPD Drug utilization 
To examine the utilization of COPD drugs listed in Table 3, both the national drug 
code (NDC) number and drug name in the databases were used through the following 
information sources: Red Book (Thomson Healthcare, 2008), Drugs@FDA 
(http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm), the U.S. Food and 
Drug Administration (FDA) Orange Book 
(http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm), and NDC directory 
(http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm). The above sources 
have drug information such as NDC number, dosage form, route of administration etc. 
More details can be found in the footnotes to Table 3. 
The number of patients using different drugs and number of prescriptions of 
COPD drugs claimed were calculated. Person-years of exposure to albuterol and 
levalbuterol were calculated as the sum of years of drug supply since the prescription 
index date (first fill or refill of albuterol and levalbuterol) for all eligible study subjects. 
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All the prescription claims were for those drugs prescribed at outpatient encounters and 
physician office visits. Neither inpatient nor ED prescriptions were recorded in the 
pharmacy claim database. However, the charge of and payment for drugs in 
hospitalization and at ED visit were included in the health service claims database. 
 
Healthcare and drug expenditures 
Expenditures on health services and prescription drugs were measured in terms of 
total expenditures (using claim “charge” variable in the databases) and Medicaid 
payments. The results were also expressed as US$ per patient per year as appropriate. 
 
Statistical analysis 
Descriptive statistics of categorical variables (such as sex) included frequency and 
percentage. Descriptive statistics of continuous variables (such as number of 
hospitalizations and drug expenditures) included mean, standard deviation (SD), 
minimum, quartile 1 (Q1), median, Q3, and maximum [or interquartile range (IQR, = Q3 
− Q1) and range (= max − min)]. All analyses were performed using SAS version 9.2 
(SAS Institute, Inc., Cary, NC, USA). 
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Objective 2: Comparative Effectiveness of Albuterol and Levalbuterol in COPD 
Patients 
Inclusion and exclusion criteria 
The following patients were considered for the comparison of clinical 
effectiveness between albuterol and levalbuterol: those who had a COPD diagnosis 
between January 1, 1999 and December 31, 2009, were aged 45 years and older at first 
diagnosis of COPD during the enrollment and younger than 65 years of age at the study 
end, treated with albuterol or levalbuterol, had at least 1-year enrollment (i.e., newly 
diagnosed COPD patients) before the prescription index date (the date on which a COPD 
patient filled his/her first albuterol or levalbuterol prescription which could be identified 
in the pharmacy claim databases), and were followed for at least 1 year since prescription 
index date, no matter preexisting or newly-diagnosed COPD patients. If a patient’s first 
COPD diagnosis in the database was identified within the first year of her/his enrollment, 
then the patient was grouped into preexisting COPD; and if the diagnosis date was after 
the first year of enrollment, the patient was classified into newly diagnosed COPD. That 
is, the eligible study subjects for this objective were a subsample of those in Objective 1. 
(See Figure 5) 
Based on intention-to-treat analysis, all subjects were followed until the end date 
of the health insurance coverage, the date of death, or December 31, 2010, whichever 
occurred first. Those COPD patients whose first diagnosis was at younger than 45 years 
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of age were excluded, because COPD diagnosis is more sensitive and specific in older 
than 45 years population and with age increase. Those COPD patients who were 65 years 
or older at the study end were excluded too because the prescription benefits of dually 
eligible beneficiaries shifted from Medicaid to Medicare Part D since January 2006. Also 
excluded were those patients who had a diagnosis of alpha-1 antitrypsin (AAT) 
deficiency (ICD-9-CM code 273.4, AAT deficiency) and/or who ever used AAT 
augmentation therapy (see Table 3). 
 
 
Figure 3. Patient Cohorts of Chronic Obstructive Pulmonary Disease for 
Comparison of Albuterol and Levalbuterol. 
 
Baseline characteristics 
The date of filling (or refilling) the first prescription of albuterol or levalbuterol in 
the pharmacy claims databases was used as the prescription index date. Demographic 








and the presence of comorbidities were recorded. Severity of COPD and overall health 
status were captured by using information on hospitalizations, ED visits, ambulatory care 
visits, and prescription drug use previously received (Table 32). 
 
Independent variables 
Among the independent variables in Table 32, those coexisting medical 
conditions (or comorbidities) such as cardiovascular diseases (CVDs) are usually 
associated with hospitalization, ED visit, and mortality in COPD patients, and have 
important impact on prognosis and management of COPD.1,3,5,30,31 And therefore, the 
study considered them in propensity score matching and the subsequent regression 
modeling. The codes used to identify CVDs and other health conditions are shown in 
Table 5 below. 
Lifestyle, biometric factors, and primary care use [such as smoking status 
(including exposure to secondhand smoke), body mass index (BMI), and evaluation and 
management of chronic diseases], are also major risk factors for COPD and/or important 
predictors of healthcare resource utilization.1,5,16,61 Thus, available information in the 




Table 5. Diagnosis Codes Used to Identify Cardiovascular Diseases (CVDs) and 
Other Medical Conditions.* 
ICD-9-CM Code† Code Information 
410–414 Ischemic heart disease; including acute myocardial infarction 
(AMI), 410 
428 Heart failure 
427 Cardiac dysrhythmias; including atrial fibrillation, 427.31 
430–438 Cerebrovascular disease 
401–405 Hypertensive disease 
















Neurotic depression/ Dysthymic disorder 
Reactive depressive psychosis/ psychogenic depressive psychosis 
Major depressive disorder, single episode 
Major depressive disorder, recurrent episode 
Depressive disorder, not elsewhere classified 
Adjustment disorder with depressed mood/ brief depressive reaction 
Prolonged depressive (adjustment) reaction 
Adjustment disorder with mixed anxiety and depressed mood/ 
Adjustment reaction with anxiety and depression 
Acute reaction to major stress with depressive symptoms 
Mixed adjustment reaction with depressive symptoms 
Separation anxiety disorder 
Anxiety states 






Secondary malignant neoplasm of lung/ Cancer metastatic to lung 
Primary lung cancer 
 
Personal history of malignant neoplasm of bronchus and lung 














Other and unspecified hyperlipidemia 
494 Bronchiectasis30 
493 Asthma 
* Codes were found at www.findacode.com and www.medicalhomeportal.org/link/4040 
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(a pdf file). 
† ICD-9-CM Code = International Classification of Diseases, Ninth Revision, Clinical 
Modification. 
 
Table 6. Diagnosis and Service/Procedure Codes of Smoking etc.* 
Code 
Category 
Code Code Information 
HCPCS† S4995 Smoking cessation gum 
 S9075 Smoking cessation treatment 
 S9453 Smoking cessation classes, non-physician provider, per 
session 
 G8093 Newly diagnosed chronic obstructive pulmonary disease 
(COPD) patient documented to have received smoking 
cessation intervention, within 3 months of diagnosis 
(WARNING: Code Deleted 2011-01-01) 
 G0375 SMOKING AND TOBACCO USE CESSATION 
COUNSELING VISIT; INTERMEDIATE, GREATER 
THAN 3 MINUTES UP TO 10 MINUTES (WARNING: 
Code Deleted 2008-01-01) 
 G0376 SMOKING AND TOBACCO USE CESSATION 
COUNSELING VISIT: INTENSIVE, GREATER THAN 3 
MINUTES UP TO 10 MINUTES (WARNING: Code 
Deleted 2008-01-01) 
 G0436 Smoking and tobacco cessation counseling visit for the 
asymptomatic patient; intermediate, greater than 3 minutes, 
up to 10 minutes 
 G0437 Smoking and tobacco cessation counseling visit for the 
asymptomatic patient; intensive, greater than 10 minutes 
 G8402 Tobacco (smoke) use cessation intervention, counseling 
(WARNING: Code Deleted 2011-01-01) 
 G8403 Tobacco (smoke) use cessation intervention not counseled 
(WARNING: Code Deleted 2011-01-01) 
 G8453 Tobacco use cessation intervention, counseling (WARNING: 
Code Deleted 2011-01-01) 
 G8455 Current tobacco smoker 
 G8456 Current smokeless tobacco user (WARNING: Code Deleted 
2011-01-01) 
 G8686 Currently a tobacco smoker or current exposure to 




Code Code Information 
 G8688 Currently a smokeless tobacco user (eg, chew, snuff) and no 
exposure to secondhand smoke (WARNING: Code Deleted 
2012-01-01) 
 G8690 Current tobacco smoker or current exposure to secondhand 
smoke (WARNING: Code Deleted 2012-01-01) 
 G8692 Current smokeless tobacco user (eg, chew, snuff) and no 
exposure to secondhand smoke (WARNING: Code Deleted 
2012-01-01) 
 G9016 Smoking cessation counseling, individual, in the absence of 
or in addition to any other evaluation and management 
service, per session (6-10 minutes) [demo project code only] 
 C9801 Smoking and tobacco cessation counseling visit for the 
asymptomatic patient; intermediate, greater than 3 minutes, 
up to 10 minutes (WARNING: Code Deleted 2011-01-01) 
 C9802 Smoking and tobacco cessation counseling visit for the 
asymptomatic patient; intensive, greater than 10 minutes 
(WARNING: Code Deleted 2011-01-01) 
CPT† 99406–
99407 
Smoking and tobacco use cessation counseling visit 
 4000F Tobacco use cessation intervention, counseling (COPD, 
CAP, CAD, Asthma)(DM)(PV) 
 4001F Tobacco use cessation intervention, pharmacologic therapy 
(COPD, CAD, CAP, PV, Asthma) (DM)(PV) 









E/M Services; Consultations; New or Established Patient 









New Patient Preventive Medicine Services 
 
Established Patient Preventive Medicine Services 
 
Counseling Risk Factor Reduction and Behavior Change 
Intervention 








Complex Chronic Care Management Services 
 
Chronic Care Management Services 
ICD-9† 649.00–
649.04 
649.0 Tobacco use disorder complicating pregnancy, 
childbirth, or the puerperium 
 305.1 Nondependent abuse of drugs; Tobacco use disorder 
Tobacco dependence 
Excludes: history of tobacco use (V15.82), smoking 
complicating pregnancy (649.0), tobacco use disorder 
complicating pregnancy (649.0) 
 989.84 Toxic effect of other substances, chiefly nonmedicinal as to 
source; tobacco 
 V15.82 Personal history presenting hazards to health; history of 
tobacco use 
Excludes: tobacco dependence (305.1) 





Body Mass Index between 25–29, adult (V85.21–V85.25) 
Body Mass Index between 30–39, adult (V85.30–V85.39) 
Body Mass Index 40 and over, adult (V85.41–V85.45) 
* Codes were identified from website Find-A-Code: http://www.findacode.com/ on March 
1, 2015. 
† CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure 
Coding System; ICD-9 = International Classification of Diseases, Ninth Revision. 
 
Propensity score matching 
To reduce selection bias between these two treatment groups (albuterol and 
levalbuterol), propensity score matching was used to control for confounding factors by 
baseline characteristics and thus to compare patients with similar observed 
characteristics.41,62-64 A set of covariates were used to calculate the propensity score. See 
Table 32 for these independent variables which covered patient demographic 
 34 
characteristics [such as age and sex], COPD severity (measured by COPD-related health 
services utilization and COPD drugs use in previous year), asthma status, and overall 
health in the previous year (measured by coexisting medical conditions and health 
services utilization in previous year). Patients prescribed levalbuterol were then matched 
1:5 with those prescribed albuterol using propensity score caliper matching.65 The 
matching was made only if both scores agreed to within a caliper of 0.1 times the 
standard deviation of the scores. Data from unmatched patients were excluded. The 
procedure of PROC LOGISTIC in SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) 




The primary outcome was the number of COPD-related hospitalizations and ED 
visits during follow-up (≥ 1 year following prescription index date). Secondary outcomes 
were all-cause hospitalizations and ED visits. When an ED visit was followed by a 
hospitalization the same day, then it counts only once as a hospitalization. 
Hospitalizations and ED visits were chosen because they are usually the indicator of 
COPD management, which are also the objectives of COPD management in Healthy 
People 2020.5,18 In addition, hospitalizations and ED visits cost much more than other 




Descriptive statistics were conducted using frequency and proportion for 
categorical data, and mean, median, and interquartile range for continuous variables to 
describe health services utilization after index date (i.e., during the follow-up period). 
Because the count variables were over-dispersed (i.e., variance much larger than 
the mean), negative binomial regression was used to compare the difference in the 
number of hospitalizations and ED visits between the two treatment groups, while 
adjusted for matched pairs and follow-up time. The independent variables at 10% level of 
significance in the stepwise selection procedure were included in the final, negative 
binomial regression analysis, while the demographic variables (age, sex, health plan etc.) 
were always included in the model. All analyses were performed using SAS. The 
regression results are shown using adjusted regression coefficients and their 95% 




To evaluate the robustness of the above data analysis, sensitivity analyses were 
conducted. The main analysis was repeated by 1:1 propensity score matching. Second 
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sensitivity analysis was the negative binominal regression on all the eligible patients who 
met inclusion criteria, rather than only those patients identified by the PSM. Thirdly, the 
study used number of all the COPD-related health services utilization (hospitalization and 
ED visits + outpatient services and physician office visits) as a composite outcome 
measure to see if albuterol and levalbuterol have different outcome. 
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Objective 3: Cost-Consequence Analysis of Albuterol and Levalbuterol in South 
Carolina Medicaid Programs 
The cost-consequence analysis was to assess the change of health services 
utilization and costs for levalbuterol and albuterol before and after the initiation of these 
two drugs. The study subjects were those 1:1 matched patients on propensity scores 
between albuterol and levalbuterol users, identified in Study Objective 2. After PSM, 
these patients had similar characteristics at baseline; and thus the consequence difference 
would be more likely attributable to the use of albuterol and levalbuterol. 
This sub-study was from the SC Medicaid payer’s perspective. The costs were 
defined as the dollar amount paid for by SC Medicaid (instead of charged amount). Direct 
health service and drug costs one (1) year before (pre-index) and one year after albuterol 
or levalbuterol initiation (post-index) were collected and compared. All costs were 
adjusted to 2010 U.S. dollar (US$) values using the Gross Domestic Product (GDP) price 
index (see http://meps.ahrq.gov/about_meps/Price_Index.shtml). 
The health services costs were those of inpatient and outpatient services, and ED, 
physician office, and other ambulatory care visits. The medication costs were costs of 
albuterol and levalbuterol, other COPD (or asthma) medications, and non-COPD drugs. 
DPIs of albuterol and levalbuterol were not available in the U.S. market. The 
CFC-containing albuterol and levalbuterol products were withdrawn from the market. 
Also, other oral albuterol and levalbuterol products such as tablet and syrup were not 
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included in the CCA as oral drugs were not recommended comparing to inhalers. In 
addition, a very small number of patients were initially prescribed HFA-containing 
levalbuterol. And therefore, the cost-consequence analysis (CCA) then examined 
albuterol and levalbuterol nebulizers only. Using National Drug Code and its related 
information, the dosage form of inhalation solution for nebulization of albuterol and 
levalbuterol was identified. 
 
Statistical analysis 
Difference-in-difference (DID) univariate test and DID regression were performed 
to compare differences in direct medical costs before and after prescription index date 
between racemic albuterol and levalbuterol groups. Fixed-effects solution (SolutionF) and 
type 3 tests of fixed effects (tests3) were used.66 All analyses were performed using the 




CHAPTER 4: RESULTS 
 
Study Objective 1: Patient Characteristics, Healthcare Resource Utilization, Drug 
Use, and Health and Drug Expenditures 
Profile of patient characteristics 
The study identified 100,138 patients in total who had at least one COPD 
diagnosis. 78,264 (78.16%) enrolled in FFS plan, 18,525 (18.50%) had both FFS and 
HMO coverage during the enrollment period, and 3349 (3.34%) were HMO patients. 
Among these 100,138 patients with COPD, 90,217 (90.1%) had consistent information 
on demographics and enrollment. Please see Figure 4 for the information incompleteness 




100,138 Patients with a primary or secondary diagnosis of chronic obstructive 
pulmonary disease 
    
 5705 Did not have demographic information  94,433 
 221 Had inconsistent information on age, sex, 
race/ethnicity, and education 
 94,212 
 441 Various enrollment start dates  93,771 
 301 Various enrollment end dates  93,470 
 58 Enrollment end dates were earlier than start dates  93,412 
 12 COPD diagnosis dates were earlier than 
enrollment start dates 
 93,400 
 2319 COPD diagnosis dates were later than enrollment 
end dates 
 91,081 
 864 Patients who used albuterol or levalbuterol after 
their enrollment end dates 
 90,217 
    
90,217 Patients with COPD who had consistent information on demographics and 
enrollment 
Figure 4. Patient Information Consistency Check. 
 
Table 7 below shows the overall demographic and socioeconomic characteristics 
of 90,217 patients with COPD among SC Medicaid enrollees from 1999 to 2010. 
Approximately 60% were female patients. More than half (53.11%) were White and 
about one third (34.02%) were African American. 71,241 (78.97%) patients enrolled in 
fee-for-service program, 16,131 (17.88%) had both FFS and HMO coverage during the 
enrollment period, and 2,845 (3.15%) were HMO patients. Almost 80% of patients had 
missing values on education level; and thus the variable “education” was not included in 
the further data analysis hereinafter due to the risk of sample-size decrease. 
The average length of enrollment in Medicaid of these patients was 6.4 years. The 
time period from enrollment start to the 1st COPD diagnosis and from the 1st diagnosis to 
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study end were 3.0 and 3.3 years, respectively. The number (59,588) of newly diagnosed 
COPD patients was twice as large as that (30,629) of preexisting COPD patients. The 
total person-years of disease and prescription follow-up were 300,269 and 186,915, 
respectively (Table 8). Disease follow-up is defined as the time period from the 1st 
COPD diagnosis to study end; and prescription follow-up is the time between first use of 
albuterol or levalbuterol to study end. 
The mean age at first COPD diagnosis was 52.2 years. Almost half (42.36%) of 
the patients were within the 45–64 years of age group. At the end of the study period, the 
mean age of these COPD patients was 55.5 years. 
45,143 (~50.0% out of 90,217 patients with COPD diagnosis) patients had ever at 
least one prescription claim for either albuterol or levalbuterol. The average follow-up 
time from first claim for albuterol or levalbuterol to the study end was 4.1 years. 
 
Table 7. Demographic and Socioeconomic Characteristics of Patients with Chronic 
Obstructive Pulmonary Disease (COPD). 
Characteristic N=90,217 (100%) 
Age of years at first diagnosis of COPD (mean ±SD) 52.2 ± 22.7 
Age group at first diagnosis  
  < 18 10,475 (11.61%) 
  18–44 14,813 (16.42%) 
  45–64 38,213 (42.36%) 
  ≥ 65 26,716 (29.61%) 
Age of years at the end of study period (mean ±SD) 55.5 ± 22.7 
Death at the study end 26,103 (28.93%) 
Sex (frequency missing=1 (0.00%))  
  Female 53,763 (59.59%) 
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Characteristic N=90,217 (100%) 
  Male 36,453 (40.41%) 
Race and ethnic group  
  White 47,916 (53.11%) 
  Black 30,694 (34.02%) 
  Hispanic, American Indian, and Asian 1,069 (1.18%) 
  Other/ Unknown/ missing 10,538 (11.68%) 
Health plan  
  Fee for Service (FFS) 71,241 (78.97%) 
  FFS & Health Maintenance Organization (HMO) 16,131 (17.88%) 
  HMO 2,845 (3.15%) 
Percent below poverty line (frequency missing=1,444 (1.6%))  
  Mean ±SD 16.2 ± 6.3 
  Median, interquartile range, range 15.6, 8.2, (0–75.6) 
Education (frequency missing=71,960 (79.8%))  
  Less than high school 11,422 (62.56%) 
  High school, special education, and vocational training 6,352 (34.79%) 
  Some college 483 (2.65%) 
Length of enrollment in years  
Mean ±SD 6.4 ± 3.9 
  Median, interquartile range, range 6.0, 7.2, (0.01–11.99) 
Years from enrollment start to 1st COPD diagnosis  
Mean ±SD 3.1 ± 3.0 
  Median, interquartile range, range 2.2, 4.0, (0.00–11.99) 
Number of patients whose 1st COPD diagnosis was within 1 year 
of enrollment (preexisting COPD) 
30,629 (33.95%) 
Number of patients whose 1st COPD diagnosis was beyond 1 
year of enrollment (newly diagnosed COPD) 
59,588 (66.05%) 
Years from 1st COPD diagnosis to study end  
Mean ±SD 3.3 ± 2.9 
  Median, interquartile range, range 2.4, 4.0, (0.00–11.99) 
Follow-up years from first claim of albuterol or levalbuterol*  
Mean ±SD 4.1 ± 3.2 
  Median, interquartile range, range 3.4, 5.1, (0.00–11.99) 
SD = standard deviation 
* Based on the number (45,143) of patients who used albuterol or levalbuterol 
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0 109 42 55 67 25  




0 111.7 45.72 58.83 71.07 25.36  




0 75.56 11.64 15.6 19.85 8.21  
enrollment period in years 
6.37 
±3.88 
0.01 11.99 2.91 5.99 10.06 7.15 575084.14 
years from 1st diagnosis to 
the study end 
3.33 
±2.9 
0 11.99 0.98 2.41 4.95 3.97 300269.23 




0 11.99 1.32 3.4 6.44 5.12 186915.01 
period in years from 
enrollment start to 1st 
diagnosis of COPD 
3.05 
±2.95 
0 11.99 0.6 2.15 4.61 4.01 274814.9 
* SD=standard deviation. 
Variable “median poverty” means poverty level determined by percent below applicable poverty line by zip code; “Follow-up years” 
indicates time period in years from prescription index date to the study end for those patients who used albuterol or levalbuterol, no. 




Table 9 shows the number of DIFFERENT diagnoses per patient with COPD 
during a patient’s entire enrollment period (i.e., history of health problems). On average, 
a patient had 51.4 differing diagnoses in her/his enrollment, and all the patients had 
13,282 unique diagnoses in 1999–2010. In total, 90,217 patients had 4,635,286 medical 
conditions. 
 











51.38 46.59 1.00 607.00 18.00 38.00 69.00 51.00 
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Table 10 below presents 20 more diagnoses among these COPD patients. These 
diagnoses represent the most common previous or coexisting medical conditions in this 
population. The descriptive statistics here gave the study a clue which health problems 
could be considered for data analysis afterward (e.g., for Objective 2). 
The most commonly seen COPD related diagnoses (highlighted in Table 10) 
were 496 (Chronic airway obstruction, not elsewhere classified) which 73,013 (80.9% 
out of 90,217) patients were diagnosed at least once during their enrollment period, 
followed by 491.21 (Obstructive chronic bronchitis; with (acute) exacerbation) in 27,998 
(31.0%) patients, 491.20 (Obstructive chronic bronchitis; without exacerbation) in 
15,526 (17.2%) patients, and 492.8 (Other emphysema) in 15,028 (16.7%) patients. 
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1 496 496—Chronic airway obstruction, not elsewhere classified 
Chronic: nonspecific lung disease, obstructive lung disease, 
obstructive pulmonary disease [COPD] NOS 
Excludes: chronic obstructive lung disease [COPD] 
specified (as) (with): allergic alveolitis (495.0-495.9), 
asthma (493.2), bronchiectasis (494.0-494.1), bronchitis 
(491.20-491.22): with emphysema (491.20-491.22), 
decompensated (491.21); emphysema (492.0-492.8) 
Note: This code is not to be used with any code from 
categories 491-493 
73013 1.575 1.575 
2 4019 401.9—Essential hypertension; unspecified 52204 1.126 2.701 
3 78605 786.05—Shortness of breath 39040 0.842 3.544 
4 78650 786.50—Chest pain, unspecified 38671 0.834 4.378 
5 78900 789.00—Abdominal pain; unspecified site 31996 0.690 5.068 
6 3051 305.1—Nondependent abuse of drugs; Tobacco use disorder 
Tobacco dependence 
Excludes: history of tobacco use (V15.82), smoking 
complicating pregnancy (649.0), tobacco use disorder 
complicating pregnancy (649.0) 
31230 0.674 5.742 
7 7295 729.5—Pain in limb 31194 0.673 6.415 
8 4011 401.1—Essential hypertension; benign 31081 0.671 7.085 
9 7862 786.2—Cough 
Excludes: cough: psychogenic (306.1), smokers' (491.0), 
with hemorrhage (786.39) 
30802 0.665 7.750 
10 49390 493.90—Asthma, unspecified; unspecified 30119 0.650 8.400 
11 53081 530.81—Esophageal reflux 
Gastroesophageal reflux 
Excludes: reflux esophagitis (530.11) 








12 25000 250.00—Diabetes mellitus without mention of complication 
or manifestation; 
    type II or unspecified type, not stated as uncontrolled 
Use additional code, if applicable, for associated long-term 
(current) insulin use V58.67 
29454 0.635 9.674 
13 486 486—Pneumonia, organism unspecified 
Excludes: hypostatic or passive pneumonia (514), inhalation 
or aspiration pneumonia due to foreign materials 
(507.0-507.8), pneumonitis due to fumes and vapors (506.0) 
29009 0.626 10.300 
14 49121 491.21—Obstructive chronic bronchitis; with (acute) 
exacerbation 
Acute exacerbation of chronic obstructive pulmonary 
disease [COPD] 
Decompensated chronic obstructive pulmonary disease 
[COPD] 
Decompensated chronic obstructive pulmonary disease 
[COPD] with exacerbation 
Excludes: chronic obstructive asthma with acute 
exacerbation (493.22) 
27998 0.604 10.904 
15 78609 786.09—Dyspnea and respiratory abnormalities; other 
Respiratory: distress, insufficiency 
Excludes: 
    respiratory distress: 
    following trauma and surgery (518.52) 
    newborn (770.89) 
    syndrome (newborn) (769): adult (518.52) 
    respiratory failure (518.81: 518.83-518.84): newborn 
(770.84) 
27885 0.602 11.505 
16 78079 780.79—Other malaise and fatigue 
Asthenia NOS 
Lethargy 
Postiviral (asthenic) syndrome 
Tiredness 








17 4660 466.0—Acute bronchitis 
Bronchitis, acute or subacute: fibrinous, membranous, 
pneumococcal, purulent, septic, viral, with tracheitis 
Croupous bronchitis 
Tracheobronchitis, acute 
Excludes: acute bronchitis with chronic obstructive 
pulmonary disease (491.22) 
26983 0.582 12.672 




26945 0.581 13.253 
19 5990 599.0—Urinary tract infection, site not specified 
Pyuria 
Excludes: Candidiasis of urinary tract (112.2), urinary tract 
infection of newborn (771.82) 
Use additional code to identify organism, such as 
Escherichia coli [E. coli] (041.41-041.19) 
26845 0.579 13.832 
20 4280 428.0—Congestive heart failure, unspecified 
Congestive heart disease 
Right heart failure (secondary to left heart failure) 
Excludes: fluid overload NOS (276.69) 
26347 0.568 14.401 
21 V5869 
† 
V58.69—Long-term (current) use of other medications 
Long term current use of methadone for pain control 
Long term current use of opiate analgesic 
Other high-risk medications 
Excludes: methadone maintenance NOS (304.00), 
methodone use NOS (304.00) 
25473 0.550 14.950 
… …  … … … 
36 49120 491.20—Obstructive chronic bronchitis; without 
exacerbation 
Emphysema with chronic bronchitis 










E849.9—Place of occurrence; unspecified place 15358 0.331 21.454 
38 4928 492.8—Other emphysema 
Emphysema (lung or pulmonary): NOS, centriacinar, 




Unilateral hyperlucent lung 
Excludes: emphysema: 
with chronic bronchitis (491.20-491.22), compensatory 
(518.2), due to fumes and vapors (506.4) 
interstitial (518.1): newborn (770.2), mediastinal (518.1), 
surgical (subcutaneous) (998.81), traumatic (958.7), with 
chronic bronchitis (491.22) 
15028 0.324 21.778 
… …  … … … 
182 A61§  5164 0.111 48.196 
… …  … … … 
* obs= observation number, from most common to least frequent. It means this unique diagnosis 
occurred in how many patients. The list is incomplete. Totally, there were 13,282 different 
diagnoses. 
Dx= ICD-9 diagnosis code 
Code information was extracted from http://www.findacode.com/ on February 20 and 21, 2015. 
Count is patient number. It means the unique diagnosis (or health condition) of this row occurred 
in this “count” number of patients. 
Cum pct= cumulative percent.  
“Percent” stands for the quotient (in %) of the number of diagnosis of this row divided by the 
total number of diagnoses (i.e., 4,635,286). The cumulative percent is the sum of percentage from 
row 1 to this row. 
 
† ICD-9 V code: (the following is cited word-by-word from 
http://www.findacode.com/code.php?set=ICD9&c=V58.69) 
“This classification is provided to deal with occasions when circumstances other than a disease or 
injury classifiable to categories 001-999 (the main part of ICD) are recorded as "diagnoses" or 
"problems." This can arise mainly in three ways: 
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“a) When a person who is not currently sick encounters the health services for some specific 
purpose, such as to act as a donor of an organ or tissue, to receive prophylactic vaccination, or to 
discuss a problem which is in itself not a disease or injury. This will be a fairly rare occurrence 
among hospital inpatients, but will be relatively more common among hospital outpatients and 
patients of family practitioners, health clinics, etc. 
“b) When a person with a known disease or injury, whether it is current or resolving, encounters 
the health care system for a specific treatment of that disease or injury (e.g., dialysis for renal 
disease; chemotherapy for malignancy; cast change). 
“c) When some circumstance or problem is present which influences the person's health status 
but is not in itself a current illness or injury. Such factors may be elicited during population 
surveys, when the person may or may not be currently sick, or be recorded as an additional factor 
to be borne in mind when the person is receiving care for some current illness or injury 
classifiable to categories 001-999. 
“In the latter circumstances the V code should be used only as a supplementary code and should 
not be the one selected for use in primary, single cause tabulations. Examples of these 
circumstances are a personal history of certain diseases, or a person with an artificial heart valve 
in situ.” 
 
‡ ICD-9 E code: E000-E999 (the following is cited word-by-word from 
http://www.findacode.com/code.php?set=ICD9&c=E849.9) 
“This section is provided to permit the classification of environmental events, circumstances, and 
conditions as the cause of injury, poisoning, and other adverse effects. Where a code from this 
section is applicable, it is intended that it shall be used in addition to a code from one of the main 
chapters of ICD-9-CM, indicating the nature of the condition. Certain other conditions which 
may be stated to be due to external causes are classified in Chapters 1 to 16 of ICD-9-CM. For 
these, the "E" code classification should be used as an additional code for more detailed analysis. 
“Machinery accidents [other than those connected with transport] are classifiable to category 
E919, in which the fourth digit allows a broad classification of the type of machinery involved.” 
 
§ This code “A61” in row 182 may be incorrect. 
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Healthcare resource utilization 
Because when counting the number of healthcare resource utilization, this study 
excluded the number of “other ambulatory” care visits which mainly consisted of durable 
medical equipment, lab test, x-rays etc., 87,419 (96.9%) out of 90,217 patients with 
COPD had at least one claim for either physician office or hospital’s outpatient, 
emergency department (ED), or inpatient service. The remaining 3.1% of patients had 
COPD diagnosis at “other ambulatory” care. 
As shown in Table 11 below, from 1999 to 2010, the SC Medicaid patients with 
COPD had an average of 1.34 all-cause hospitalizations, 4.98 ED visits, 7.96 outpatient 
services, and 20.74 physician-office visits, respectively. Taking the healthcare encounters 
(excluding “other ambulatory”) together, a patient received 35 health services on average 
in the entire enrollment time. At the level of per patient per year enrolled, the number of 
all-cause hospitalizations, emergency room (ER) visits, outpatient services, and physician 
office visits were 0.35, 1.00, 1.61, and 3.92, respectively. In total, the claimed health 
services were 3 million (3,159,365) or 621 thousand (620,941) services per year. 
When a COPD code was involved in primary or secondary diagnoses, then this 
healthcare encounter was defined as COPD related. The results of health services 
utilization related to COPD were shown in Table 12. There were totally 329,636 health 
services related to COPD and out of them155,660 were physician office visits. Out of the 
health services claimed by COPD patients, COPD-related hospitalizations accounted for 
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44% (mean) of all the hospitalizations. Overall, COPD-related health services were 21% 
(mean) of all the health services claimed by COPD patients, while the median values 

















No. of hospitalizations 
1.34 
±2.65 
0 88 0 1 2 2 120751 




0 669 0 2 5 5 449375 
No. of outpatient services 
7.96 
±15.14 
0 337 1 3 9 8 718317 
No. of physician office visits 
20.74 
±31.24 
0 641 1 9 27 26 1870922 
No. of all healthcare encounters 
35.02 
±48.18 
0 893 6 18 45 39 3159365 
No. of hospitalizations per year 
0.35 
±0.97 
0 40.58 0 0.08 0.33 0.33 31863.66 
No. of emergency department 
visits per year 
1 
±2.54 
0 147.98 0 0.3 1 1 90515.91 
No. of outpatient services per year 
1.61 
±3.82 
0 420.83 0.08 0.55 1.69 1.61 145362.22 




0 676.61 0.25 1.77 5.05 4.8 353200.05 




0 721.52 1.24 3.62 8.71 7.46 620941.84 
* SD = standard deviation. 
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Table 12. Number of COPD-Related Healthcare Resource Utilization. (N=90,217) 









number of COPD-related 
hospitalizations 
0.51 1.22 0 43 0 0 1 1 46122 
number of COPD-related emergency 
room (ER) visits 
0.79 2.71 0 188 0 0 1 1 71671 
number of COPD-related outpatient 
services 
0.62 2.52 0 296 0 0 1 1 56183 
number of COPD-related physician 
office visits 
1.73 4.38 0 124 0 0 1 1 155660 
number of COPD-related all 
healthcare encounters 
3.65 7.69 0 356 1 1 4 3 329636 
number of COPD-related 
hospitalizations per year (years from 
first COPD diagnosis to study end) 
0.46 4.21 0 365.25 0 0 0.17 0.17 41807.2 




0.54 5.38 0 365.25 0 0 0.24 0.24 49051.07 




0.33 3.2 0 508.28 0 0 0.1 0.1 29960.81 
number of COPD-related physician 
office visits per year
†
 
0.81 4.24 0 426.13 0 0 0.65 0.65 72778.93 
number of COPD-related all 
healthcare encounters per year
†
 
2.15 9.06 0 608.75 0.12 0.68 1.96 1.85 193598.01 
* COPD = chronic obstructive pulmonary disease; SD=standard deviation. 
† 26 patients’ COPD diagnosis was at the study end date (i.e., date of enrollment end, death, or December 31, 2010); and so these 
patients were excluded when calculated COPD-related healthcare resource utilization per year. 
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Health services rendered 
The health services provided by healthcare professionals were recorded using 
ICD-9 Vol. 3, Current Procedural Terminology (CPT), and Healthcare Common 
Procedure Coding System (HCPCS) procedure codes. 45,359 patients had medical 
services and/or procedures rendered in inpatient and/or emergency department services. 
These patients on average received 4.6 (± 4.0) procedures/ services. The total number of 
procedures patients received was 209,206 while the number of different procedures was 
2309 only. Table 13 shows the most frequently rendered medical services and/or 
procedures in hospitalization and ED at patient level. From the preliminary descriptive 
statistics, it seems that cardiovascular procedures and mechanical ventilation would be 
important covariates for Objective 2. 
 
Table 13. Top 20 Medical Procedures and/or Services Rendered in Inpatient or 
Emergency Department out of 2309 Unique Procedures among 45,359 Patients. 




1 3893 38.93—Venous catheterization, not elsewhere classified 
Excludes: 
    that for cardiac catheterization (37.21-37.23) 
    that for renal dialysis (38.95) 
    that with guidance (electrocardiogram) (fluoroscopy) 
(ultrasound) (38.97) 
9702 4.63753 
2 9904 99.04—Transfusion of packed cells 9535 4.55771 
3 9604 96.04—Insertion of endotracheal tube 6473 3.09408 
4 8856 88.56—Coronary arteriography using two catheters 6066 2.89953 
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    Coronary arteriography by: 
        Judkins technique 
        Ricketts and Abrams technique 
    Direct selective coronary arteriography using two catheters 
Excludes: intra-operative fluorescence vascular angiography 
(88.59) 
5 3722 37.22—Left heart cardiac catheterization 
Excludes: that with catheterization of right heart (37.23) 
5995 2.86560 
6 8853 88.53—Angiocardiography of left heart structures 
    Angiocardiography of: 
        aortic valve 
        left atrium 
        left ventricle (outflow tract) 
Excludes: intra-operative fluorescence vascular angiography 
(88.59) 
that combined with right heart angiocardiography (88.54) 
5601 2.67727 
7 9671 96.71—Continuous invasive mechanical ventilation for less than 96 
consecutive hours 
4532 2.16629 
8 4516 45.16—Esophagogastroduodenoscopy [EGD] with closed biopsy 
    Biopsy of one or more sites involving esophagus, stomach, 
and/or duodenum 
4524 2.16246 
9 4513 45.13—Other endoscopy of small intestine 
    Esophagogastroduodenoscopy [EGD] 
Excludes: that with biopsy (45.14, 45.16) 
3954 1.89000 
10 9672 96.72—Continuous invasive mechanical ventilation for 96 
consecutive hours or more 
3595 1.71840 
11 8872 88.72—Diagnostic ultrasound of heart 
    Echocardiography 
    Transesophageal echocardiography 
Excludes: 
    echocardiography of heart chambers (37.28) 
    intracardiac echocardiography (ICE) (37.28) 
3485 1.66582 
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    intravascular (IVUS) imaging of coronary vessels (00.24) 
12 3324 33.24—Closed [endoscopic] biopsy of bronchus 
    Bronchoscopy (fiberoptic) (rigid) with: 
        brush biopsy of "lung" 
        brushing or washing for specimen collection 
        excision (bite) biopsy 
    Diagnostic bronchoalveolar lavage (BAL) 
    Mini-bronchoalveolar lavage [mini-BAL] 
    Transbronchoscopic needle aspiration [TBNA] of bronchus 
Excludes: 
    closed biopsy of lung, other than brush biopsy of "lung" 
(33.26, 33.27) 
    whole lung lavage (33.99) 
3164 1.51238 
13 8891 88.91—Magnetic resonance imaging of brain and brain stem 
Excludes: 
    intraoperative magnetic resonance imaging (88.96) 
    laser interstitial thermal therapy [LITT] of lesion or tissue of 
brain under guidance (17.61) 
    real-time magnetic resonance imaging (88.96) 
3138 1.49996 
14 3995 39.95—Hemodialysis 
    Artificial kidney 
    Hemodiafiltration 
    Hemofiltration 
    Renal dialysis 
Excludes: peritoneal dialysis (54.98) 
2492 1.19117 
15 4523 45.23—Colonoscopy 
    Flexible fiberoptic colonoscopy 
Excludes: 
    endoscopy of large intestine through artificial stoma (45.22) 
    flexible sigmoidoscopy (45.24) 
    rigid proctosigmoidoscopy (48.23) 
    transabdominal endoscopy of large intestine (45.21) 
2261 1.08075 
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16 9390 93.90—Non-invasive mechanical ventilation 
    Bi-level airway pressure 
    BiPAP without (delivery through) endotracheal tube or 
tracheostomy 
    CPAP without (delivery through) endotracheal tube or 
tracheostomy 
    Mechanical ventilation NOS 
    Non-invasive positive pressure (NIPPV) 
    Non-invasive PPV 
    NPPV 
    That delivered by non-invasive interface: 
        face mask 
        nasal mask 
        nasal pillow 
        oral mouthpiece 
        oronasal mask 
Excludes: invasive (through endotracheal tube or tracheostomy) 
continuous mechanical ventilation (96.70-96.72) 
Note: Patients admitted on non-invasive mechanical ventilation that 
subsequently require invasive mechanical ventilation; code both 
types of mechanical ventilation. 
2225 1.06355 
17 4311 43.11—Percutaneous [endoscopic] gastrostomy [PEG] 
    Percutaneous transabdominal gastrostomy 
1701 0.81307 
18 9907 99.07—Transfusion of other serum 
    Transfusion of plasma 
Excludes: 
    injection [transfusion] of: 
        antivenin (99.16) 
        gamma globulin (99.14) 
1559 0.74520 
19 3491 34.91—Thoracentesis 1472 0.70361 
20 8622 86.22—Excisional debridement of wound, infection, or burn 
    Removal by excision of: 
1395 0.66681 
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        devitalized tissue 
        necrosis 
        slough 
Excludes: 
    debridement of: 
        abdominal wall (wound) (54.3) 
        bone (77.60-77.69) 
        muscle (83.45) 
        of hand (82.36) 
        nail (bed) (fold) (86.27) 
        nonexcisional debridement of wound, infection, or burn 
(86.28) 
        open fracture site (79.60-79.69) 
        pedicle or flap graft (86.75) 
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Table 14 below outlines the most frequent healthcare procedures (coded by CPT 
and HCPCS) which were provided in ambulatory care departments (i.e., physician office, 
hospital outpatient and ER, and other ambulatory care facility). The evaluation and 
management services (CPT codes 99212–99214 [Office or Other Outpatient Services], 
99282–99285 [Emergency Department Services], and 99231, 99232, and 99238 
[Hospital Inpatient Services]) were used in most patients. E.g., 59,680 patients had office 
or other outpatient visit for the evaluation and management 15-minute services, out of 




Table 14. Most Frequently Rendered Healthcare Procedures in Ambulatory Care 




99213 99213—Office or other outpatient visit for the evaluation and 
management of an established patient, which requires at least 2 of these 
3 key components: An expanded problem focused history; An expanded 
problem focused examination; Medical decision making of low 
complexity. Counseling and coordination of care with other physicians, 
other qualified health care professionals, or agencies are provided 
consistent with the nature of the problem(s) and the patient's and/or 
family's needs. Usually, the presenting problem(s) are of low to moderate 
severity. Typically, 15 minutes are spent face-to-face with the patient 
and/or family. 
59680 1.18893 
71020 71020—Radiologic examination, chest, 2 views, frontal and lateral. 54708 1.08988 
99214 99214—Office or other outpatient visit for the evaluation and 
management of an established patient, which requires at least 2 of these 
3 key components: A detailed history; A detailed examination; Medical 
decision making of moderate complexity. Counseling and/or coordination 
of care with other physicians, other qualified health care professionals, or 
agencies are provided consistent with the nature of the problem(s) and the 
patient's and/or family's needs. Usually, the presenting problem(s) are of 
moderate to high severity. Typically, 25 minutes are spent face-to-face 
with the patient and/or family. 
52564 1.04717 
36415 36415—Collection of venous blood by venipuncture. 50647 1.00898 
85025 85025—Blood count; complete (CBC), automated (Hgb, Hct, RBC, 
WBC and platelet count) and automated differential WBC count. 
48917 0.97451 
99283 99283—Emergency department visit for the evaluation and 
management of a patient, which requires these 3 key components: An 
expanded problem focused history; An expanded problem focused 
examination; and Medical decision making of moderate complexity. 
Counseling and/or coordination of care with other physicians, other 
qualified health care professionals, or agencies are provided consistent 
with the nature of the problem(s) and the patient's and/or family's needs. 
Usually, the presenting problem(s) are of moderate severity. 
45614 0.90871 
71010 71010—Radiologic examination, chest; single view, frontal. 43280 0.86221 
80048 80048—Basic metabolic panel (Calcium, total) 40471 0.80625 
99284 99284—Emergency department visit for the evaluation and 40308 0.80301 
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management of a patient, which requires these 3 key components: 
    A detailed history; 
    A detailed examination; and 
    Medical decision making of moderate complexity. 
Counseling and/or coordination of care with other physicians, other 
qualified health care professionals, or agencies are provided consistent 
with the nature of the problem(s) and the patient's and/or family's needs. 
Usually, the presenting problem(s) are of high severity, and require 
urgent evaluation by the physician or other qualified health care 
professionals but do not pose an immediate significant threat to life or 
physiologic function. 
93010 93010—Electrocardiogram, routine ECG with at least 12 leads; 
interpretation and report only. 
39933 0.79554 
80053 80053—Comprehensive metabolic panel. 36808 0.73328 
99212 99212—Office or other outpatient visit for the evaluation and 
management of an established patient, which requires at least 2 of these 
3 key components: A problem focused history; A problem focused 
examination; Straightforward medical decision making. Counseling 
and/or coordination of care with other physicians, other qualified health 
care professionals, or agencies are provided consistent with the nature of 
the problem(s) and the patient's and/or family's needs. Usually, the 
presenting problem(s) are self limited or minor. Typically, 10 minutes are 
spent face-to-face with the patient and/or family. 
36172 0.72061 
99232 99232—Subsequent hospital care, per day, for the evaluation and 
management of a patient, which requires at least 2 of these 3 key 
components: An expanded problem focused interval history; An 
expanded problem focused examination; Medical decision making of 
moderate complexity. Counseling and/or coordination of care with other 
physicians, other qualified health care professionals, or agencies are 
provided consistent with the nature of the problem(s) and the patient's 
and/or family's needs. Usually, the patient is responding inadequately to 
therapy or has developed a minor complication. Typically, 25 minutes 
are spent at the bedside and on the patient's hospital floor or unit. 
35625 0.70971 
99285 99285—Emergency department visit for the evaluation and 
management of a patient, which requires these 3 key components within 
the constraints imposed by the urgency of the patient's clinical condition 
33316 0.66371 
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and/or mental status: A comprehensive history; A comprehensive 
examination; and Medical decision making of high complexity. 
Counseling and/or coordination of care with other physicians, other 
qualified health care professionals, or agencies are provided consistent 
with the nature of the problem(s) and the patient's and/or family's needs. 
Usually, the presenting problem(s) are of high severity and pose an 
immediate significant threat to life or physiologic function. 
99238 99238—Hospital discharge day management; 30 minutes or less. 30686 0.61132 
92015 92015—Determination of refractive state. 30427 0.60616 
99282 99282—Emergency department visit for the evaluation and 
management of a patient, which requires these 3 key components: An 
expanded problem focused history; An expanded problem focused 
examination; and Medical decision making of low complexity. 
Counseling and/or coordination of care with other physicians, other 
qualified health care professionals, or agencies are provided consistent 
with the nature of the problem(s) and the patient's and/or family's needs. 
Usually, the presenting problem(s) are of low to moderate severity. 
29928 0.59622 
93005 93005—Electrocardiogram, routine ECG with at least 12 leads; tracing 
only, without interpretation and report. 
28419 0.56616 
T1015 T1015—Clinic visit/encounter, all-inclusive. 28065 0.55910 
88305 88305—Level IV - Surgical pathology, gross and microscopic 
examination. 
28024 0.55829 
80061 80061—Lipid panel. 26947 0.53683 
99231 99231—Subsequent hospital care, per day, for the evaluation and 
management of a patient, which requires at least 2 of these 3 key 
components: A problem focused interval history; A problem focused 
examination; Medical decision making that is straightforward or of low 
complexity. Counseling and/or coordination of care with other 
physicians, other qualified health care professionals, or agencies are 
provided consistent with the nature of the problem(s) and the patient's 
and/or family's needs. Usually, the patient is stable, recovering or 
improving. Typically, 15 minutes are spent at the bedside and on the 
patient's hospital floor or unit. 
26096 0.51988 
84443 84443—Thyroid stimulating hormone (TSH) 25299 0.50400 
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85027 85027—Blood count; complete (CBC), automated (Hgb, Hct, RBC, 
WBC and platelet count). 
25051 0.49906 




Prescription drug utilization 
Because there is not a unique code or name for a specific prescription drug or 
combination drug, it is hard for this study to rank the number of prescriptions used by the 
SC Medicaid patients with COPD in 1999–2010. That is, the descriptive statistics the 
research did for diagnosis, health service, and medical procedures at hospitalization and 
ED visits cannot be duplicated here for drug utilization. 
Totally, 81,035 out of 90,217 patients filled and refilled 11,544,205 prescriptions. 
On average, a patient had 128.0 claims for prescription drugs during the entire 
enrollment period, or 21.2 prescription claims per patient per year. In each year, all the 
SC Medicaid patients with COPD had almost 2 million (1,909,564) prescriptions 
claimed. 
The results in Table 15 also showed the distribution of the number of 
prescriptions (a continuous variable) at each level of categorical variables (e.g., age 
group and gender). And the difference between groups was compared. The number of 
prescriptions was not normally distributed; and thus the Kruskal Wallis test and 
Wilcoxon-Mann-Whitney test were used. 
There was significant difference in number of prescriptions claimed between four 
age groups. Patients in the group of 18–44 years of age had the most average number of 
prescription claims (mean ±SD, 171.6 ± 212.4), while the other two older patient groups 
did not. And even the age group of 65 years and older had the fewest average number of 
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prescriptions (79 ± 112.1). This is because the age group here is based on the age of 
patient at their first diagnosis of COPD during enrollment. And the study period is from 
1999 to 2010. Subsequently, there would be some patients were covered by Medicare 
Part D for prescription benefits since January 1, 2006. As a result, the claims for 
pharmacy in SC Medicaid program would then decrease. 
Female patients claimed statistically significantly more prescriptions (148.1 ± 
195.8) than males (98.3 ± 146.0). White patients had more prescriptions filled and 
refilled. Patients in the 4th quartile of economic status (i.e., poorest) were prescribed more 
drugs. The newly diagnosed COPD patients had more prescriptions than those with 
preexisting conditions. The patients enrolled in HMO program had significantly fewer 








Minimum Maximum Lower Quartile Median Upper Quartile Quartile Range 
No. of prescriptions per patient 128 ±179 0 2222 11 56 176 165 
No. of prescriptions per patient per year 21.2 ±30.6 0 1719.1 2.9 12.7 30.2 27.3 
 
Table 16. Number of prescriptions per patient by age group. 
Age Group n 
Mean 
±SD 
Minimum Maximum Lower Quartile Median Upper Quartile Range Quartile Range 






































































Table 17. Number of prescriptions per patient per year by age group. 
Age Group n Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile Quartile Range 
< 18 10475 14.4 20.1 0 583.2 3.8 8.6 17.8 14 
18-44 14813 28.8 38.1 0 1365.2 7.5 19.9 38.6 31.1 
45-64 38213 26.4 34.5 0 1719.1 5.3 18.7 37.8 32.6 
≥ 65 26716 12.1 17.8 0 967.9 0.3 5 18.2 17.9 
 
Table 18. Number of prescriptions per patient by sex. 
sex n Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile 
Male 36453 98.3 146 0 2095 8 40 130 
Female 53763 148.1 195.8 0 2222 15 71 209 
 
Table 19. Number of prescriptions per patient per year by sex. 
sex n Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile 
Male 36453 18.1 25.4 0 690.9 2.2 10.2 25.5 
Female 53763 23.2 33.5 0 1719.1 3.5 14.7 33.2 
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Table 20. Number of prescriptions per patient by race and ethnic group. 
Race and Ethnic Group n Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile 
White 47916 133 180.6 0 2222 13 62 186.5 
Black 30694 111.1 161.5 0 1679 9 46 149 
Hispanic, American Indian, and Asian 1069 75.6 148.1 0 1600 5 22 73 
Other/ unknown/ missing 10538 159.4 213.5 0 2095 14 73 223 
 
Table 21. Number of prescriptions per patient per year by race and ethnic group. 
Race and Ethnic Group n Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile 
White 47916 23.4 31.5 0 1719.1 3.7 15.2 33.6 
Black 30694 17 25.2 0 963.4 2 9.5 24 
Hispanic, American Indian, and Asian 1069 15 24.5 0 384.7 1.6 6.6 17.9 
Other/ unknown/ missing 10538 23.7 38.5 0 1365.2 3.3 14.3 33.8 
 
Table 22. Number of prescriptions per patient by COPD History. 
 
n Mean Std Dev Minimum Lower Quartile Median Upper Quartile Maximum 
newly diagnosed 59588 132.7 177.5 0 12 64 188 2222 
preexisting 30629 118.7 181.5 0 10 45 148 1936 
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Table 23. Number of prescriptions per patient per year by COPD History. 
  n Mean Std Dev Minimum Lower Quartile Median Upper Quartile Maximum 
newly diagnosed 59588 16.9 20.7 0 2 9.9 24.8 501.6 
preexisting 30629 29.5 42.6 0 6 19.8 41 1719.1 
 
Table 24. Number of prescriptions per patient by Health Plan Type. 









Fee-for-Service (FFS) 71241 114.8 165 0 2222 8 47 160 
FFS & Health Maintenance Organization 
(HMO) 
16131 199.8 225.3 0 1933 44 114 274 
HMO 2845 51.2 84.3 0 1074 8 23 61 
 
Table 25. Number of prescriptions per patient per year by Health Plan Type. 









Fee-for-Service (FFS) 71241 18.9 27.9 0 1494.5 1.8 10.8 27.4 
FFS & Health Maintenance Organization 
(HMO) 
16131 32.1 39.9 0 1719.1 9.9 22.7 43.5 




COPD drugs utilization 
All the COPD related drugs in Table 3 were identified and calculated at both the 
prescription and patient level. Out of the COPD prescriptions claimed by the patients, 
ranked No. 1 was albuterol (372,851) used by 36,342 patients, followed by albuterol and 
ipratropium combination (172,369) by 19,766 patients, LABA and ICS combination 
(166,513) by 18,850 patients, and leukotriene-receptor antagonist (147,947) by 10,853 
patients. The number of levalbuterol prescriptions was only 32,242 used by 5865 patients, 
less than one tenth of albuterol, and just before LABA (31,655) by 5366 patients, ICS 
(7965) by 1652 patients, other SABA (5190) by 956 patients, mast-cell stabilizer (3058) 
by 675 patients, systemic steroids (472) by 357 patients, and AAT augmentation therapy 
(338) by 8 patients only. In total, 49,692 (55.1%) out of 90,217 COPD patients ever used 
at least one prescription drug listed in Table 3. 
Among these 14 classes of COPD-related drugs showed in Table 3, patients in 
SC Medicaid program used 1244 different combinations (not meaning such combination 
drugs as Combivent [albuterol and ipratropium combination] and Advair HFA 
[fluticasone and salmeterol combination]) in their entire enrollment period from 1999 to 
2010. Table 26 shows the most frequently used COPD drug combinations. Almost 20% 
(n=9849) of the 49,692 patients who had at least one COPD prescription claim used 
albuterol only. Merely 610 (1.23%) patients used just levalbuterol. 1749 patients ever 
used albuterol as well as levalbuterol. 
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Table 26. Most Frequently Used Combination of COPD Drugs.* 
All COPD Drugs Used No. of Patients Percent 
Alb 9849 19.82 
Abl & Ipr Comb 4091 8.23 
Alb+LABA & ICS Comb 2439 4.91 
Alb+Abl & Ipr Comb 2236 4.50 
Alb+LTRA 1434 2.89 
Alb+Abl & Ipr Comb +LABA & ICS Comb 1392 2.80 
LABA & ICS Comb 1316 2.65 
Abl & Ipr Comb +LABA & ICS Comb 1220 2.46 
Alb+LABA & ICS Comb +LTRA 972 1.96 
Alb+Ipr 951 1.91 
Alb+Leval 793 1.60 
Alb+LABA & ICS Comb + Tio 642 1.29 
Leval 610 1.23 
Alb+Abl & Ipr Comb +Ipr 603 1.21 
Alb+Leval+LTRA 599 1.21 
Alb+Abl & Ipr Comb +LABA & ICS Comb + Tio 581 1.17 
LTRA 557 1.12 
Alb+Tio 542 1.09 
Alb+Abl & Ipr Comb +Ipr+ LABA & ICS Comb 507 1.02 
Alb+Abl & Ipr Comb +LABA & ICS Comb +LTRA 453 0.91 
Alb+LABA 371 0.75 
Tio 359 0.72 
MX 357 0.72 
Alb+Leval+ LABA & ICS Comb +LTRA 357 0.72 
Ipr 335 0.67 
Alb+Ipr+ LABA & ICS Comb 304 0.61 
Alb+MX 283 0.57 
LABA 260 0.52 
Alb+Abl & Ipr Comb + LTRA 248 0.50 
Alb+Abl & Ipr Comb +Tio 242 0.49 
* Alb = albuterol; comb = combination; ICS = inhaled corticosteroid; ipr = ipratropium; 
LABA = long-acting beta2 agonist; leval = levalbuterol; LTRA = leukotriene-receptor 




Health care expenditures 
In 1999–2010, the total health care expenditures (charge) on patients who were ever diagnosed COPD were US$10.7 billion, 
while the SC Medicaid programs paid US$2.6 billion. On average, the SC Medicaid programs paid US$7350.70 per patient per year 
for COPD patients, of which US$2524.30 were for COPD-related health care and US$4826.40 for non-COPD related. 
 
Table 27. Total Healthcare Expenditures of and SC Medicaid Payments for COPD in 1999–2010. 




Total charge (US$) 118,363.9 207,863.9 51,275.0 123,561.2 10,678,435,837.0 
Total COPD-related charge (US$) 33,274.6 82,022.7 3,105.5 32,010.0 3,001,936,578.0 
ER charge related to COPD (US$) 7,216.5 24,455.1 0.0 1,546.5 651,047,395.2 
Inpatient charge related to COPD (US$) 21,543.4 66,654.3 0.0 12,736.3 1,943,581,295.2 
Outpatient charge related to COPD (US$) 1,519.2 5,718.6 0.0 85.0 137,056,039.4 
Physician-office charge related to COPD (US$) 266.8 996.1 0.0 200.0 24,066,710.3 
Other ambulatory charge related to COPD (US$) 2,728.8 8,759.4 210.0 1,224.6 246,185,137.8 
Total non-COPD-related charge (US$) 85,089.3 176,405.0 29,152.2 84,578.6 7,676,499,258.8 
ER charge not related to COPD (US$) 11,727.2 37,247.9 924.0 8,898.3 1,057,996,683.3 
Inpatient charge not related to COPD (US$) 29,811.8 98,464.4 0.0 19,579.1 2,689,535,565.3 
Outpatient charge not related to COPD (US$) 11,005.4 25,252.5 2,769.0 11,907.4 992,870,578.1 
Physician-office charge not related to COPD (US$) 5,838.2 19,001.9 1,312.3 5,090.8 526,702,954.7 
Other ambulatory charge not related to COPD (US$) 26,706.6 76,963.8 7,738.0 24,158.1 2,409,393,477.4 
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Total payment (US$) 28,354.1 64,017.2 7,081.7 26,090.7 2,558,017,871.0 
Total COPD-related payment (US$) 6,170.6 21,018.6 428.1 2,635.2 556,689,880.2 
ER payment related to COPD (US$) 1,285.8 5,989.9 0.0 115.0 116,004,707.7 
Inpatient payment related to COPD (US$) 3,856.6 16,112.9 0.0 876.0 347,930,709.5 
Outpatient payment related to COPD (US$) 147.9 765.0 0.0 5.6 13,343,528.0 
Physician-office payment related to COPD (US$) 103.0 359.6 0.0 73.5 9,293,203.5 
Other ambulatory payment related to COPD (US$) 777.2 4,566.8 39.9 258.2 70,117,731.5 
Total non-COPD-related payment (US$) 22,183.5 56,432.9 4,709.2 19,287.9 2,001,327,990.7 
ER payment not related to COPD (US$) 2,100.8 8,379.6 91.4 1,021.0 189,530,899.3 
Inpatient payment not related to COPD (US$) 6,057.6 25,641.2 0.0 1,219.4 546,500,890.5 
Outpatient payment not related to COPD (US$) 1,326.7 3,557.0 213.4 1,103.6 119,695,138.1 
Physician-office payment not related to COPD (US$) 1,849.0 6,086.5 317.0 1,563.6 166,806,979.7 
Other ambulatory payment not related to COPD (US$) 10,849.3 37,091.3 1,486.9 7,427.5 978,794,083.1 
 
Table 28. Charge and Payment per Patient per Year. 
 Mean Standard Deviation Median Interquartile Range 
Total charge per patient per year (US$) 30538.80 96282.50 9406.00 23422.90  
Total COPD-related charge per patient per year (US$) 11681.00 63823.30 672.50 6183.90  
Total non-COPD-related charge per patient per year (US$) 18857.80 64514.20 5410.80 14760.00  
Total payment per patient per year (US$) 7350.70 24547.30 1405.30 5216.00  
Total COPD-related payment per patient per year (US$) 2524.30 16207.40 93.00 552.30  
Total non-COPD-related payment per patient per year (US$) 4826.40 16356.50 948.70 3711.90  
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Prescription drug expenditures 
As mentioned above in the section of “Health services rendered,” 81,035 COPD 
patients had at least one prescription claim. At the patient level, there was one person 
whose total drug charge was zero (0). And the number of zero payment was 104. That is, 
the SC Medicaid program did not pay 104 patients for drugs; however, the amount 
charged ($4537.71) was small. Out of the total charge on all drugs which was not 
reimbursed, $3307.21 was COPD drugs. 
As shown in Table 29 below, the SC Medicaid program paid $742 million 
($741,892,922) out of $1 billion ($1,031,982,980) claimed amount for all drugs. The 
charge on and payment for COPD drugs were $120 million ($120,499,866) and $92 
million ($92,580,902), respectively. The SC Medicaid program’s reimbursement for all 
drug claims was almost 75% (741892922.91/1031982980.40 = 71.9%), and this rate for 
all COPD drugs was a bit more than 75% (92580902.73/120499866.09=76.8%). 
The mean and median charges on all claimed drugs at patient level were $12,735 
(SD, 25,636) and $4540 (IQR, 13,526), respectively, while the mean and median 
payments were $9155 (±18,419) and $3175 (IQR, 9734), respectively. Even without 
normality test, it seems these variables (charges and payments) would not be normally 
distributed, but highly skewed. 
Table 30 shows the total charge on and Medicaid payment for each COPD drug 
or drug class listed in Table 3. And Table 31 presents the claim and payment per 
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prescription of albuterol, levalbuterol, ipratropium, albuterol-ipratropium combination, 
and LABA-ICS combination drugs. The total payment for albuterol, 
albuterol-ipratropium combination, and levalbuterol by SC Medicaid was $9.5 million 
($9,524,448), $16.9 million ($16,881,881) and $5.3 million ($5,250,882), respectively. 
It is noteworthy that the mean and median charge on and payment for alpha-1 
antitrypsin (AAT) augmentation therapies (AT) were $244,156 (mean charge) $165,492 
(mean payment), $263,419 (median charge), $158,019 (median payment), respectively. 
The total charge on and payment for AATAT were $1,953,249 and $1,323,936, 
respectively. The average expense per patient on AATAT was the highest among all the 
COPD drugs and drug classes. 
As shown in Table 31, the average charge on and payment for albuterol per 
prescription were $45.08 and $23.17, respectively, while the corresponding numbers for 
levalbuterol were $192.83 (3.3 times more than albuterol) and $143.93 (5.2 times more 




Table 29. Expenditures on and SC Medicaid Payment for All Drugs and COPD-Related Drugs. (N=81,035) 







Total charge on all drugs 12735.03 25636.56 0 1054733.20 934.97 4540.39 14461.42 1031982980.40 
Total payment for all drugs 9155.22 18419.81 0 892555.76 563.66 3175.53 10298.19 741892923.91 
Total charge on COPD drugs 1487.01 4962.54 0 379085.29 0 111.30 1019.89 120499866.09 
Total payment for COPD drugs 1142.48 3627.16 0 316127.86 0 72.51 763.43 92580903.73 
Ratio of COPD drug charge over 
all drug charge 
0.13 0.2 0 1 0 0.02 0.17  
Ratio of COPD drug payment 
over all drug payment 





Table 30. Total Claim Charge and Total Payment (US$) for Claim per COPD Drug and Drug Class per Patient.* 
 No. of patient Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile Sum 
Charge on albuterol 36342 499 1227 0 102672 51 153 457 18137416 
Payment for albuterol 36342 262 564 0 19219 29 78 247 9524448 
Charge on levalbuterol 5865 1169 2874 1 46654 147 364 969 6854979 
Payment for levalbuterol 5865 895 2126 0 39440 112 287 769 5250882 
Charge on LABA-ICS comb 18850 1797 2720 1 54814 273 751 2136 33867574 
Payment for LABA-ICS comb 18850 1561 2291 0 24946 231 649 1868 29423982 
Charge on albuterol-ipratropium 19766 1095 2795 1 194395 124 314 1018 21648794 
Payment for albuterol-ipratropium 19766 854 1763 0 31670 95 244 795 16881881 
Charge on ipratropium 8094 790 1729 0 29369 84 220 692 6391049 
Payment for ipratropium 8094 422 953 0 14951 41 105 353 3415670 
Charge on AATAT 8 244156 111574 70179 360531 156539 263419 341312 1953249 
Payment for AATAT 8 165492 99283 26123 296618 89804 158019 252775 1323936 
Charge on ICS 1652 502 950 4 10457 83 170 493 829091 
Payment for ICS 1652 424 792 0 8687 69 147 421 699629 
Charge on LABA 5366 664 1092 1 14375 111 284 716 3562899 
Payment for LABA 5366 551 894 0 12246 92 237 603 2955416 
Charge on LTRA 10853 1531 2168 1 52973 228 703 2029 16620523 
Payment for LTRA 10853 1313 1737 0 16667 197 612 1754 14249893 
Charge on mast cell stabilizer 675 354 830 9 9899 63 118 292 238971 
Payment for mast cell stabilizer 675 278 665 0 9079 50 95 233 187458 
Charge on MX 4646 504 841 0 15587 52 188 618 2342640 
Payment for MX 4646 370 643 0 11557 34 129 454 1719792 
Charge on other SABA 956 450 1175 4 21042 54 115 358 430430 
Payment for other SABA 956 361 903 2 15595 42 92 288 345497 
Charge on systemic corticosteroid 357 34 69 0 855 9 16 32 12077 
Payment for systemic steroid 357 22 59 0 825 3 8 18 7875 
Charge on tiotropium 6431 1183 1734 1 19684 209 518 1348 7610175 
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 No. of patient Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile Sum 
Payment for tiotropium 6431 1025 1476 0 10698 190 447 1164 6594546 
* AATAT = alpha-1 antitrypsin augmentation therapy; Comb = combination; ICS = inhaled corticosteroid; LABA = long-acting beta2 agonist; 





Table 31. Charge on and Payment for Albuterol, Levalbuterol, and Other COPD drugs per Prescription (Rx). (US$) 
 Mean Std Dev Minimum Maximum Lower Quartile Median Upper Quartile 
Charge on albuterol Rx 45.08 41.59 0 1730.38 24.99 34.45 49.12 
Payment for albuterol Rx 23.17 17.44 0 402.4 11.8 19.9 30.68 
Charge on albuterol-ipratropium Rx 117.57 345.91 0.88 47244.8 70.33 92.39 135.98 
Payment for albuterol-ipratropium Rx 88.18 48.13 0 710.61 57.5 75.12 106.98 
Charge on levalbuterol Rx 192.83 416.07 0.66 28205.96 77.99 132.47 265.05 
Payment for levalbuterol Rx 143.93 105.66 0 1035.39 62.37 103.74 203.87 
Charge on LABA-ICS Rx 195.18 92.08 1.4 7830.58 161.99 188.3 221.99 
Payment for LABA-ICS Rx 169.8 41.38 0 705.71 141.13 165 199.35 
Charge on ipratropium Rx 120.41 101.62 0 2633.21 55.51 91.61 160.72 
Payment for ipratropium Rx 65.06 70.28 0 857.99 26.42 48.07 79.9 




Study Objective 2: Comparative Effectiveness Research of Albuterol and 
Levalbuterol in Terms of Healthcare Resource Utilization 
Patient Selection Flow 
Figure 5 shows patient selection flow. Among patients with consistent 
information, 45,143 patients claimed at least one albuterol or levalbuterol prescription. At 
last, there were totally 5,437 patients who met the inclusion criteria for comparative 
effectiveness research.  
 
 
90,217 Patients with a primary or secondary diagnosis of chronic obstructive pulmonary 
disease whose information on demographics and enrollment was consistent 
  
 85,620 Excluded 
  45,074 Did not claim for albuterol or levalbuterol (45,143 eligible) 
  8,836 Had a < 1-year follow-up since prescription index date (36,307) 
  24,001 Were aged < 45 years at first diagnosis of COPD or ≥ 65 years at 
study end (12,306 eligible) 
  0 Were diagnosed AAT deficiency or ever used AAT augmentation 
therapy (12,306 eligible) 
  6,869 Initially prescribed albuterol-ipratropium combination or did not 
have 1-year data before prescription index date (5,437 eligible) 
  840 Missed race and ethnicity information (those in other/ unknown/ 
missing category) 





4307 initially prescribed albuterol 
290 initially prescribed levalbuterol 
Figure 5. Patient Selection Flow Diagram. (Continued from Figure 4. Patient 
Information Consistency Check.) 
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Baseline Characteristics Before and After Propensity Score Matching 
The baseline characteristics of these 4597 patients are shown in Table 32 “Before 
propensity score matching” columns. There were significant differences in many baseline 
characteristics. And it seemed that patients in levalbuterol group were sicker than patients 
taking albuterol. For example, patients who were prescribed levalbuterol had more health 
services utilization in the previous year (only exception “number of all-cause ED visits”), 
more patients claimed for COPD medications, and larger percentage of patients had 
comorbidities. Hypertension, heavy smoking (ever or current), and asthma ever 





Table 32. Baseline Characteristics of Patients Included in the Study before and after 1:5 Matching on Propensity Scores. 



















Patients, n 4307 290    1435 287   
          
Demographic          
Age, mean (SD), y 52.5 (4.8) 53.0 (4.5) 10.37 .0945  52.7 (2.1) 53.0 (4.5) 8.23 .3419 
Female sex, % 67.6 63.8 8.00 .1823  64.6 63.8 1.74 .7870 
Race/ethnicity* 



















84.0 76.2 19.56 .0006  79.7 76.3 8.08 .2033 
Healthcare plan† 














          
COPD and general 
care (mean ±SD) 
         
Number of 
evaluation and 




3.92 (5.36) 13.84 .0285  3.54 
(2.32) 
3.86 (5.29) 7.81 .3433 
  Number of physician 




4.98 (7.12) 17.51 .0080  4.31 
(2.94) 
4.78 (6.64) 9.18 .2681 
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  Number of outpatient 
visits in previous year 
1.70 
(3.26) 
2.26 (4.29) 14.84 .0282  1.98 
(1.59) 
2.20 (4.22) 6.97 .4044 
  Number of 
emergency department 
visits in previous year 
1.06 
(2.62) 
0.90 (2.05) 6.80 .2082  1.00 
(1.08) 
0.90 (2.06) 5.89 .4811 





0.48 (1.02) 28.36 <.0001  0.34 
(0.34) 
0.41 (0.80) 10.90 .1817 
  Number of COPD 
related physician office 
visits in previous year 
0.40 
(0.97) 
0.51 (1.17) 10.68 .1031  0.47 
(0.52) 
0.51 (1.17) 4.32 .6038 
  Number of COPD 
related outpatient visits 
in previous year 
0.15 
(0.56) 
0.23 (0.66) 12.83 .0484  0.20 
(0.33) 
0.23 (0.66) 5.84 .4846 
  Number of COPD 
related emergency 




0.27 (1.19) 9.76 .1976  0.22 
(0.27) 
0.27 (1.20) 5.69 .4957 
  Number of COPD 
related hospitalizations 
in previous year 
0.10 
(0.38) 
0.21 (0.49) 25.36 .0002  0.15 
(0.21) 
0.21 (0.49) 13.65 .0941 




25.8 (31.9) 10.05 .1137  24.6 
(13.5) 
25.6 (31.9) 4.14 .6066 
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filled in previous year 
  Number of 
prescriptions for COPD 




1.12 (3.10) 7.98 .2335  1.07 
(1.27) 
1.11 (3.11) 1.96 .8141 
          
COPD medication use 
in previous year (%) 
         




0.63 0.69 0.78 .8960  .77 .70 0.82 .9009 
  Short-acting 
anticholinergic 
2.00 1.72 2.02 .7470  2.1 1.7 2.54 .7026 
  LABA 2.39 2.41 0.15 .9808  2.7 2.4 1.33 .8394 
  Long-acting 
anticholinergic 
2.07 3.45 8.45 .1166  2.4 3.1 4.69 .4474 
  Inhaled 
corticosteroid 
3.53 3.45 0.44 .9424  3.7 3.5 1.12 .8633 
  LABA-steroid 
combination drug 
6.92 11.03 14.44 .0086  10.6 10.8 0.68 .9164 
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  Systemic 
corticosteroid 
13.23 15.52 6.51 .2690  13.3 15.3 5.77 .3626 
  Methylxanthine 2.79 3.79 5.65 .3185  2.9 3.8 5.01 .4173 
  (Mast-cell stabilizer)          
  Leukotriene-receptor 
antagonist 
3.97 3.45 2.76 .6582  4.1 3.5 3.28 .6209 
          
Previous or coexisting 
medical conditions 
(%) 
         
  Ischemic heart 
disease 
19.2 27.9 20.68 .0003  24.3 27.9 8.10 .2038 
  Heart failure 14.6 24.1 24.30 <.0001  20.5 23.3 6.91 .2777 
  Cardiac arrhythmia 8.8 12.4 11.68 .0391  11.5 12.2 2.16 .7366 
  Cerebrovascular 
disease 
 9.0 13.8 15.02 .0070  11.7 13.9 6.67 .2899 
  Hypertension 53.1 55.5 4.81 .4289  55.5 55.4 0.14 .9827 
  Acute upper 
respiratory infection 
11.0 13.1 6.60 .2603  12.4 12.9 1.47 .8195 
  Osteoporosis  3.1  4.1 5.63 .3221  3.1 4.2 5.97 .3310 
  Anxiety and 
depression 
25.0 34.8 21.57 .0002  29.6 34.2 9.73 .1277 
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  Lung cancer 1.88 1.72 1.18 .8490  1.3 1.7 3.40 .5812 
  Diabetes 29.3 32.1 6.00 .3170  31.7 32.4 1.49 .8170 
  Hyperlipidemia 26.5 29.7 6.99 .2421  28.9 30.0 2.45 .7040 
  Heavy smoking 61.5 66.2 9.75 .1124  64.0 66.2 4.68 .4715 
  Overweight and 
obesity 
11.0 12.1 3.26 .5850  11.7 12.2 1.50 .8150 
  Asthma ever 
diagnosed 
47.7 43.8 7.83 .1983  47.0 43.2 7.71 .2346 






Descriptive Statistics of Outcome Measures 
After 1:5 propensity score matching (Table 32 right columns), 287 levalbuterol 
users were matched very well to 1435 albuterol users. There is a significant difference 
only in race/ethnicity variable. Mean follow-up of these 1722 patients were 4.5 years (SD, 
2.6; median and IQR, 4.1 and 4.2). The total follow-up time was 7790 patient-years. 
Table 33 shows the descriptive statistics of health services utilization by 1722 
patients who were prescribed albuterol (n=1435) and levalbuterol (n=287). Taking their 
similar, balanced baseline characteristics into consideration, it seems (not statistically 
tested yet) that levalbuterol did not have less healthcare resources utilization than 
albuterol. However, this might result from longer follow-up in levalbuterol group or any 
imbalance in PSM. Let’s see negative binomial regression results shown in Table 34, 
which further controlled for these confounding factors as well as length of follow-up. 
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Table 33. Healthcare Resources Utilization of Patients 1:5 Matched on Propensity Scores. 
 
Albuterol + Levalbuterol 
(n=1722) 

























4 (8) 12273  
10.0 
(13.6) 
6 (10) 2879 




38 (54) 91843 
 51.0 
(47.2) 
36 (51) 73202  
65.0 
(56.9) 
44 (67) 18641 
No. of COPD-related hospitalizations 
and ED visits 
2.3 (4.6) 1 (3) 3938 
 
2.0 (4.2) 1 (2) 2873  3.7 (6.0) 1 (4) 1065 




3 (7) 11167 
 
5.6 (8.9) 2 (6) 8058  
10.8 
(15.6) 
5 (13) 3109 
No. of all-cause hospitalizations and 
ED visits per year 
2.2 (3.7) 1.1 (2.2) 3840.2 
 
2.2 (3.8) 1.1 (2.2) 3162.5  2.4 (3.0) 1.3 (2.4) 677.7 
No. of all-cause, all health services 
utilization per year 
13.0 
(11.9) 
10.2 (12.5) 22382.8 
 12.5 
(11.2) 
9.7 (12.4) 17921.7  
15.5 
(14.4) 
12.6 (13.2) 4461.1 
No. of COPD-related hospitalizations 
and ED visits per year 
0.6 (1.3) 0.2 (0.7) 1064.6 
 
0.6 (1.2) 0.1 (0.6) 802.3  0.9 (1.6) 0.4 (1.1) 262.3 
No. of COPD-related, all health 
services utilization per year 
1.7 (2.5) 0.7 (1.9) 2848.3 
 




Difference in Health Services Utilization between Albuterol and Levalbuterol 
Table 34 shows that there was significant difference in the number of 
COPD-related hospitalizations and emergency department (ED) visits [more precisely, 
the natural logarithm (log) of the number] during patient’s follow-up between 
levalbuterol and albuterol groups after controlling for other confounding factors 
(including length of follow-up). Patients who used levalbuterol had more hospitalizations 
and ED visits during follow-up than albuterol users. The parameter estimate was 0.4164. 
It means levalbuterol users had an expected log count 0.4164 (95% confidence interval 
[CI], 0.0683–0.7645) more than albuterol users. As exp(0.4164) = 1.516, we can say that 
levalbuterol users had 51.6% (interval, 7%–115%) more COPD-related hospitalizations 
and ED visits than albuterol users. 
Other significant predictors of number of COPD-related hospitalizations and ED 
visits included age, gender, healthcare plan, preexisting or newly diagnosed COPD, 
heavy smoking, number of COPD-related ED visits in previous year, and hypertension 
(highlighted in Table 34). 
After excluding some variables which were not significant in the original model 
(P > 0.1), albuterol or levalbuterol use remained a significant predictor of the number of 




Table 34. Negative Binomial Regression on Number of COPD-related 
Hospitalizations and Emergency Department Visits during Follow-up of Patients 
1:5 Matched on Propensity Scores. (n=1722) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -7.1625 0.8355 -8.8000 -5.5250 73.49 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.4164 0.1776 0.0683 0.7645 5.50 0.0190 
age 1 0.0669 0.0144 0.0386 0.0951 21.51 <.0001 
sex 1 0.6487 0.1512 0.3523 0.9452 18.40 <.0001 
Race and ethnic 
group (White vs. 
non-White) 
1 0.0464 0.1604 -0.2679 0.3607 0.08 0.7725 
Healthcare plan (FFS 
only vs. HMO 
involved) 
1 0.3197 0.1602 0.0058 0.6337 3.99 0.0459 
Preexisting or newly 
diagnosed COPD 
1 -0.8422 0.1859 -1.2065 -0.4778 20.53 <.0001 
Heavy smoking 
(Yes/No) 
1 1.3691 0.1608 1.0539 1.6843 72.48 <.0001 
Ischemic heart 
disease (Yes/No) 
1 0.2478 0.1895 -0.1235 0.6192 1.71 0.1908 
Heart failure (Yes/No) 1 0.5422 0.1967 0.1568 0.9277 7.60 0.0058 
Cardiac arrhythmia 
(Yes/No) 
1 0.0901 0.2208 -0.3427 0.5229 0.17 0.6833 
Cerebrovascular 
disease (Yes/No) 
1 -0.1319 0.2126 -0.5486 0.2848 0.39 0.5349 
Hypertension 
(Yes/No) 
1 -0.4893 0.1670 -0.8167 -0.1620 8.58 0.0034 
Anxiety and 
depression (Yes/No) 
1 0.0275 0.1786 -0.3225 0.3775 0.02 0.8777 
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Analysis Of Maximum Likelihood Parameter Estimates 











1 -0.3407 0.2193 -0.7705 0.0890 2.41 0.1202 
Osteoporosis (Yes/No) 1 0.0269 0.3961 -0.7495 0.8033 0.00 0.9458 
Lung cancer (Yes/No) 1 0.7520 0.5289 -0.2846 1.7887 2.02 0.1551 
Diabetes mellitus 
(Yes/No) 
1 0.0257 0.1718 -0.3110 0.3624 0.02 0.8809 
hyperlipidemia 
(Yes/No) 
1 0.0297 0.1883 -0.3394 0.3987 0.02 0.8747 
Asthma ever 
diagnosed (Yes/No) 
1 -0.3247 0.1546 -0.6276 -0.0218 4.41 0.0357 
Overweight and 
obesity (Yes/No) 
1 0.0520 0.2348 -0.4081 0.5121 0.05 0.8246 
No. of hospitalizations 
in previous year 
1 0.3693 0.1343 0.1060 0.6326 7.56 0.0060 
No. of emergency 
department (ED) 
visits in previous year 
1 0.0231 0.0300 -0.0357 0.0819 0.59 0.4410 
No. of outpatient 
services in previous 
year 
1 0.0419 0.0237 -0.0045 0.0884 3.13 0.0768 
No. of physician office 
visits in previous year 
1 -0.0103 0.0168 -0.0432 0.0226 0.38 0.5387 
No. of COPD-related 
hospitalizations in 
previous year 
1 -0.1968 0.2062 -0.6010 0.2074 0.91 0.3399 
No. of COPD-related 
ED visits in previous 
year 
1 0.5486 0.1219 0.3096 0.7875 20.24 <.0001 
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Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
No. of COPD-related 
outpatient services in 
previous year 
1 -0.1414 0.0893 -0.3165 0.0336 2.51 0.1134 
No. of COPD-related 
physician office visits 
in previous year 
1 -0.0047 0.0637 -0.1295 0.1201 0.01 0.9407 
No. of evaluation and 
management services 
in previous year 
1 0.0385 0.0260 -0.0124 0.0894 2.20 0.1383 
No. of COPD 
prescriptions in 
previous year 
1 0.0114 0.0393 -0.0656 0.0885 0.08 0.7711 




1 -0.0080 0.0029 -0.0137 -0.0024 7.82 0.0052 
Other SABA use in 
previous year (Y/N) 
1 -1.9811 0.6922 -3.3378 -0.6244 8.19 0.0042 
Ipratropium use in 
previous year (Y/N) 
1 0.4357 0.4736 -0.4926 1.3639 0.85 0.3576 
LABA use in previous 
year (Y/N) 
1 -0.5393 0.4806 -1.4813 0.4027 1.26 0.2618 
LABA-ICS 
combination use in 
previous year (Y/N) 
1 -0.0104 0.2677 -0.5350 0.5142 0.00 0.9691 
Tiotropium use in 
previous year (Y/N) 
1 0.2454 0.4708 -0.6773 1.1682 0.27 0.6021 
Methylxanthine use 
in previous year (Y/N) 
1 -0.0126 0.4605 -0.9151 0.8899 0.00 0.9782 
LTRA use in previous 
year (Y/N) 
1 -0.6733 0.3978 -1.4530 0.1065 2.86 0.0906 
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Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
ICS use in previous 
year (Y/N) 
1 -0.4192 0.4282 -1.2584 0.4201 0.96 0.3276 
Systemic steroid use 
in previous year (Y/N) 
1 -0.2184 0.2352 -0.6794 0.2426 0.86 0.3531 





Table 35. Negative Binomial Regression on Number of COPD-related 
Hospitalizations and Emergency Department Visits during Follow-up of Patients 
1:5 Matched on Propensity Scores. Results after excluding some nonsignificant factors 
(P > .1). (n=1722) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -7.3095 0.7973 -8.8722 -5.7468 84.05 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.3713 0.1729 0.0324 0.7101 4.61 0.0318 
age 1 0.0678 0.0139 0.0405 0.0950 23.80 <.0001 
sex 1 0.6817 0.1441 0.3992 0.9641 22.38 <.0001 
Healthcare plan (FFS 
only vs. HMO 
involved) 
1 0.3379 0.1533 0.0375 0.6383 4.86 0.0275 
Preexisting or newly 
diagnosed COPD 
1 -0.7796 0.1755 -1.1235 -0.4357 19.74 <.0001 
Heavy smoking 
(Yes/No) 
1 1.3780 0.1534 1.0774 1.6786 80.72 <.0001 
Heart failure 
(Yes/No) 
1 0.6548 0.1775 0.3068 1.0028 13.60 0.0002 
Hypertension 
(Yes/No) 
1 -0.4544 0.1530 -0.7543 -0.1546 8.83 0.0030 
Asthma ever 
diagnosed (Yes/No) 




1 0.3137 0.0928 0.1319 0.4955 11.44 0.0007 
No. of outpatient 
services in previous 
year 
1 0.0459 0.0227 0.0014 0.0905 4.08 0.0434 
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Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
No. of emergency 
department (ED) 
visits in previous 
year 
1 0.6120 0.1176 0.3815 0.8425 27.08 <.0001 
No. of outpatient 
services in previous 
year 
1 -0.1744 0.0879 -0.3466 -0.0021 3.94 0.0472 
No. of evaluation and 
management services 
in previous year 
1 0.0341 0.0172 0.0004 0.0679 3.92 0.0477 
No. of non-COPD 
prescriptions in 
previous year 
1 -0.0083 0.0025 -0.0133 -0.0033 10.53 0.0012 
Other SABA use in 
previous year (Y/N) 
1 -1.7312 0.6662 -3.0369 -0.4255 6.75 0.0094 
LTRA use in 
previous year (Y/N) 
1 -0.7385 0.3775 -1.4784 0.0014 3.83 0.0504 




For secondary outcome measure which was number of all-cause hospitalizations 
and ED visits during follow-up, there was no significant difference between levalbuterol 
and albuterol users, as shown in Table 36 and Table 37. The significant positive 
predicators included heart failure, number of ED visits in previous year, age, and male 
gender. That is, the number of all-cause hospitalizations and ED visits during follow-up 
increased if the patients had heart failure; had more ED visits in previous year; were 
older; and were male gender.  
The significant negative predicators were the use of other SABA (except albuterol 
and levalbuterol), methylxanthine, and LABA in previous year, number of non-COPD 
prescriptions in previous year, newly diagnosed COPD, number of COPD-related 
outpatient services in previous year, and overweight and obesity. That is, if a patient had 
used SABAs (except albuterol and levalbuterol), LABAs, and methylxanthine, claimed 
more non-COPD prescriptions, had more COPD-related outpatient services, or was a 
newly diagnosed COPD patient, then he/she was less likely to be hospitalized or to visit 
ED during follow-up. These factors make sense because they indicated the historical 
management of COPD and/or comorbidities (or coexisting medical conditions). But it 
remains a question why patients who were overweight and obese had less 




Table 36. Negative Binomial Regression on Number of All-cause Hospitalizations 
and Emergency Department Visits during Follow-up of Patients 1:5 Matched on 
Propensity Scores. (n=1722) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -3.9102 0.5472 -4.9827 -2.8378 51.07 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.0077 0.1271 -0.2415 0.2569 0.00 0.9515 
age 1 0.0327 0.0096 0.0140 0.0514 11.72 0.0006 
sex 1 0.3349 0.1036 0.1318 0.5380 10.45 0.0012 
Race and ethnic 
group (White vs. 
non-White) 
1 0.4579 0.1065 0.2491 0.6667 18.48 <.0001 
Healthcare plan (FFS 
only vs. HMO 
involved) 
1 0.1157 0.1081 -0.0961 0.3276 1.15 0.2843 
Preexisting or newly 
diagnosed COPD 
1 -0.3306 0.1351 -0.5954 -0.0658 5.99 0.0144 
Heavy smoking 
(Yes/No) 
1 0.7240 0.1073 0.5138 0.9343 45.56 <.0001 
Ischemic heart 
disease (Yes/No) 
1 -0.0316 0.1323 -0.2909 0.2277 0.06 0.8113 
Heart failure (Yes/No) 1 0.5046 0.1402 0.2299 0.7793 12.96 0.0003 
Cardiac arrhythmia 
(Yes/No) 
1 0.0316 0.1581 -0.2783 0.3415 0.04 0.8417 
Cerebrovascular 
disease (Yes/No) 
1 0.0636 0.1516 -0.2335 0.3607 0.18 0.6750 
Hypertension 
(Yes/No) 
1 -0.1496 0.1169 -0.3788 0.0795 1.64 0.2006 
Anxiety and 
depression (Yes/No) 
1 0.0655 0.1196 -0.1689 0.3000 0.30 0.5838 
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1 -0.2571 0.1542 -0.5593 0.0451 2.78 0.0955 
Osteoporosis (Yes/No) 1 -0.1107 0.2745 -0.6488 0.4273 0.16 0.6867 
Lung cancer (Yes/No) 1 0.1714 0.4082 -0.6286 0.9715 0.18 0.6745 
Diabetes mellitus 
(Yes/No) 
1 0.0826 0.1183 -0.1492 0.3145 0.49 0.4849 
hyperlipidemia 
(Yes/No) 
1 0.0411 0.1274 -0.2086 0.2908 0.10 0.7470 
Asthma ever 
diagnosed (Yes/No) 
1 -0.0192 0.1049 -0.2248 0.1865 0.03 0.8551 
Overweight and 
obesity (Yes/No) 
1 -0.3436 0.1651 -0.6673 -0.0199 4.33 0.0375 
No. of hospitalizations 
in previous year 
1 0.3396 0.0912 0.1609 0.5184 13.87 0.0002 
No. of emergency 
department (ED) 
visits in previous year 
1 0.0922 0.0281 0.0371 0.1473 10.76 0.0010 
No. of outpatient 
services in previous 
year 
1 0.0663 0.0180 0.0309 0.1016 13.49 0.0002 
No. of physician office 
visits in previous year 
1 -0.0054 0.0131 -0.0311 0.0202 0.17 0.6781 
No. of COPD-related 
hospitalizations in 
previous year 
1 -0.0690 0.1479 -0.3590 0.2209 0.22 0.6407 
No. of COPD-related 
ED visits in previous 
year 
1 0.1832 0.0918 0.0032 0.3632 3.98 0.0461 
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Chi-Square Pr > ChiSq 
No. of COPD-related 
outpatient services in 
previous year 
1 -0.1474 0.0701 -0.2849 -0.0099 4.41 0.0356 
No. of COPD-related 
physician office visits 
in previous year 
1 0.0157 0.0497 -0.0816 0.1131 0.10 0.7516 
No. of evaluation and 
management services 
in previous year 
1 0.0216 0.0189 -0.0154 0.0587 1.31 0.2523 
No. of COPD 
prescriptions in 
previous year 
1 0.0146 0.0263 -0.0368 0.0661 0.31 0.5772 




1 -0.0063 0.0021 -0.0105 -0.0021 8.74 0.0031 
Other SABA use in 
previous year (Y/N) 
1 -2.0086 0.5616 -3.1093 -0.9078 12.79 0.0003 
Ipratropium use in 
previous year (Y/N) 
1 -0.1419 0.3419 -0.8120 0.5282 0.17 0.6780 
LABA use in previous 
year (Y/N) 
1 -0.6751 0.3486 -1.3584 0.0081 3.75 0.0528 
LABA-ICS 
combination use in 
previous year (Y/N) 
1 -0.0369 0.1875 -0.4045 0.3306 0.04 0.8438 
Tiotropium use in 
previous year (Y/N) 
1 0.0288 0.3350 -0.6277 0.6853 0.01 0.9314 
Methylxanthine use 
in previous year (Y/N) 
1 -0.7944 0.3280 -1.4372 -0.1516 5.87 0.0154 
LTRA use in previous 
year (Y/N) 
1 -0.3628 0.2749 -0.9016 0.1759 1.74 0.1869 
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Chi-Square Pr > ChiSq 
ICS use in previous 
year (Y/N) 
1 -0.4582 0.3019 -1.0499 0.1335 2.30 0.1290 
Systemic steroid use 
in previous year (Y/N) 
1 0.0188 0.1617 -0.2981 0.3356 0.01 0.9075 




Table 37. Negative Binomial Regression on Number of All-cause Hospitalizations 
and Emergency Department Visits during Follow-up of Patients 1:5 Matched on 
Propensity Scores: Results after excluding nonsignificant (P > .1) predictors in original 
model. (n=1722) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -3.9228 0.5348 -4.9710 -2.8745 53.80 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 -0.0117 0.1252 -0.2570 0.2337 0.01 0.9258 
age 1 0.0335 0.0094 0.0151 0.0520 12.69 0.0004 
sex 1 0.3313 0.0986 0.1380 0.5246 11.28 0.0008 
Race and ethnic 
group (White vs. 
non-White) 
1 0.4219 0.1018 0.2225 0.6214 17.19 <.0001 
Preexisting or newly 
diagnosed COPD 
1 -0.3382 0.1250 -0.5832 -0.0931 7.32 0.0068 
Heavy smoking 1 0.7306 0.1043 0.5262 0.9351 49.08 <.0001 




1 -0.2684 0.1464 -0.5554 0.0186 3.36 0.0668 
Overweight and 
obesity (Yes/No) 




1 0.3170 0.0677 0.1842 0.4497 21.90 <.0001 
No. of emergency 
department (ED) 
visits in previous 
year 
1 0.0986 0.0271 0.0456 0.1516 13.28 0.0003 
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Chi-Square Pr > ChiSq 
No. of outpatient 
services in previous 
year 
1 0.0776 0.0159 0.0464 0.1088 23.83 <.0001 
No. of COPD-related 
ED visits in previous 
year 
1 0.1518 0.0877 -0.0201 0.3237 3.00 0.0835 
No. of COPD-related 
outpatient services in 
previous year 
1 -0.1393 0.0680 -0.2726 -0.0059 4.19 0.0406 
No. of non-COPD 
prescriptions in 
previous year 
1 -0.0052 0.0017 -0.0086 -0.0018 8.91 0.0028 
Other SABA use in 
previous year (Y/N) 
1 -1.8701 0.5375 -2.9237 -0.8166 12.10 0.0005 
LABA use in 
previous year (Y/N) 
1 -0.9166 0.2921 -1.4892 -0.3440 9.84 0.0017 
Methylxanthine use 
in previous year 
(Y/N) 
1 -0.7898 0.2830 -1.3445 -0.2352 7.79 0.0053 






1:1 match on propensity scores rather than 1:5 match 
When patients who used levalbuterol were 1:1 matched on propensity scores to 
patients using albuterol, the mean follow-up of these 578 patients were 4.4 years (SD, 2.5; 
median and IQR, 3.8 and 3.7). The total length of follow-up was 2,522 patient-years. The 
1:1 matching was more balanced between albuterol and levalbuterol groups than 1:5 
matching. There were no significant differences in all the variables between these two 
groups after PSM (Table 38). 
Table 39 shows the descriptive statistics after 1:1 PSM. Table 40 presents the 
negative binomial regression results of these 1:1 matched patients. Levalbuterol use (vs. 
albuterol) was not a significant predictor of the number of COPD-related hospitalizations 
and ED visits during follow-up. That is, there was no difference in the log of number of 
COPD-related hospitalizations and ED visits during follow-up between albuterol and 
levalbuterol groups after controlling for other factors. Significant predictors were heavy 
smoking (yes/no), age, methylxanthine and LABA used in previous year (yes/no, 
negative predictors), heart failure (yes/no), number of COPD prescriptions in previous 
year (continuous variable), and asthma ever diagnosed (yes/no). Similarly, Table 41 
shows that there was no difference in number of all-cause hospitalizations and ED visits 
during follow-up (secondary outcome measure) between albuterol and levalbuterol. 
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Table 38. Baseline Characteristics of Patients Included in the Study before and after 1:1 Propensity Score Matching. 



















Patients, n 4307 290    289 289   
          
Demographic          
Age, mean (SD), y 52.5 (4.8) 53.0 (4.5) 10.37 .0945  52.8 (4.7) 52.9 (4.5) 2.32 .7805 
Female sex, % 67.6 63.8 8.00 .1823  34.3 36.3 4.35 .6015 
Race/ethnicity* 














84.0 76.2 19.56 .0006  77.5 76.1 3.28 .6934 
Healthcare plan† 















          
COPD and general 
care (mean ±SD) 
         
Number of 
evaluation and 




3.92 (5.36) 13.84 .0285  4.16 
(5.31) 
3.87 (5.29) 5.48 .5102 
  Number of physician 




4.98 (7.12) 17.51 .0080  5.27 
(7.82) 
4.86 (6.83) 5.61 .5003 
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  Number of 




2.26 (4.29) 14.84 .0282  2.26 
(3.72) 
2.21 (4.22) 1.04 .9002 
  Number of 
emergency department 
visits in previous year 
1.06 
(2.62) 
0.90 (2.05) 6.80 .2082  0.81 
(1.42) 
0.90 (2.06) 5.09 .5408 





0.48 (1.02) 28.36 <.0001  0.43 
(1.08) 
0.46 (0.97) 3.04 .7149 
  Number of COPD 
related physician office 
visits in previous year 
0.40 
(0.97) 
0.51 (1.17) 10.68 .1031  0.59 
(1.42) 
0.51 (1.16) 6.41 .4416 
  Number of COPD 
related outpatient visits 
in previous year 
0.15 
(0.56) 
0.23 (0.66) 12.83 .0484  0.19 
(0.58) 
0.22 (0.66) 5.56 .5040 
  Number of COPD 
related emergency 




0.27 (1.19) 9.76 .1976  0.23 
(0.65) 
0.27 (1.19) 4.31 .6044 
  Number of COPD 
related hospitalizations 
in previous year 
0.10 
(0.38) 
0.21 (0.49) 25.36 .0002  0.20 
(0.71) 
0.20 (0.49) 0.00 1.0000 
  Number of 22.7 25.8 (31.9) 10.05 .1137  24.9 25.7 (31.9) 2.84 .7326 
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filled in previous year 
(28.8) (28.1) 
  Number of 
prescriptions for 
COPD medications 
filled in previous year 
0.90 
(2.41) 
1.12 (3.10) 7.98 .2335  1.22 
(2.95) 
1.12 (3.11) 3.43 .6804 
          
COPD Medication 
use in previous year 
(%) 
         




0.63 0.69 0.78 .8960  .35 .69 4.82 .5627 
  Short-acting 
anticholinergic 
2.00 1.72 2.02 .7470  2.8 1.7 7.01 .4000 
  LABA 2.39 2.41 0.15 .9808  1.7 2.4 4.85 .5596 
  Long-acting 
anticholinergic 
2.07 3.45 8.45 .1166  3.1 3.5 1.94 .8155 
  Inhaled 
corticosteroid 
3.53 3.45 0.44 .9424  3.8 3.5 1.85 .8241 
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  LABA-steroid 
combination drug 
6.92 11.03 14.44 .0086  12.5 11.1 4.30 .6056 
  Systemic 
corticosteroid 
13.23 15.52 6.51 .2690  14.5 15.6 2.90 .7271 
  Methylxanthine 2.79 3.79 5.65 .3185  4.8 3.8 5.10 .5396 
  (Mast-cell stabilizer)          
  Leukotriene-receptor 
antagonist 
3.97 3.45 2.76 .6582  2.8 3.5 3.98 .6320 
          
Previous or coexisting 
medical conditions 
(%) 
         
  Ischemic heart 
disease 
19.2 27.9 20.68 .0003  28.0 27.7 .77 .9261 
  Heart failure 14.6 24.1 24.30 <.0001  20.4 23.9 8.34 .3165 
  Cardiac arrhythmia 8.8 12.4 11.68 .0391  9.7 12.5 8.83 .2889 
  Cerebrovascular 
disease 
 9.0 13.8 15.02 .0070  15.9 13.8 5.84 .4831 
  Hypertension 53.1 55.5 4.81 .4289  55.4 55.4 0.00 1.0000 
  Acute upper 
respiratory infection 
11.0 13.1 6.60 .2603  14.5 13.2 4.01 .6300 
  Osteoporosis  3.1  4.1 5.63 .3221  5.2 4.2 4.92 .5543 
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  Anxiety and 
depression 
25.0 34.8 21.57 .0002  35.0 34.6 .73 .9304 
  Lung cancer 1.88 1.72 1.18 .8490  2.4 1.7 4.85 .5596 
  Diabetes 29.3 32.1 6.00 .3170  33.9 32.2 3.68 .6584 
  Hyperlipidemia 26.5 29.7 6.99 .2421  33.2 29.8 7.46 .3705 
  Heavy smoking 61.5 66.2 9.75 .1124  64.7 66.1 2.91 .7265 
  Overweight and 
obesity 
11.0 12.1 3.26 .5850  12.1 12.1 0.00 1.0000 
  Asthma ever 
diagnosed 
47.7 43.8 7.83 .1983  43.3 43.6 .70 .9331 
          
FFS = fee for service; HMO = health maintenance organization. 
* Race and ethnic groups analyzed here were White and non-White. 
† “HMO involved” includes patients who had FFS as well as HMO, and who had HMO only. The other category of “healthcare plan” 





Table 39. Health Services Utilization of the 1:1 Matched Patients on Propensity Scores during Follow-Up. 


















5.0 (9.0) 4950  
6.9 (8.3) 4 (7) 1996  
10.2 
(14.0) 
6 (10) 2954 




40 (58) 33471 
 50.5 
(45.6) 
38 (50) 14608  
65.3 
(57.2) 
44 (67) 18863 
No. of COPD-related hospitalizations 
and ED visits 
2.9 (5.2) 1 (3) 1653 
 
1.9 (3.1) 1 (2) 540  3.9 (6.5) 1 (4) 1113 




4 (9) 4795 
 
5.6 (8.2) 3 (5) 1611  
11.0 
(16.0) 
5 (13) 3184 
No. of all-cause hospitalizations and ED 
visits per year 
2.1 (2.7) 1.3 (2.2) 1232.8 
 
1.9 (2.3) 1.2 (2.0) 546.4  2.4 (3.0) 1.3 (2.3) 686.4 
No. of all-cause, all health services 
utilization per year 
14.3 
(12.8) 
11.3 (13.3) 8284.3 
 13.1 
(10.9) 
10.2 (12.1) 3797.2  
15.5 
(14.3) 
12.6 (13.2) 4487.1 
No. of COPD-related hospitalizations 
and ED visits per year 
0.7 (1.3) 0.3 (0.8) 423.9 
 
0.5 (0.9) 0.2 (0.7) 156.3  0.9 (1.6) 0.4 (1.1) 267.6 
No. of COPD-related, all health services 
utilization per year 
2.0 (2.8) 1.0 (2.6) 1163.4 
 





Table 40. Negative Binomial Regression on Number of COPD-related 
Hospitalizations and Emergency Department Visits during Follow-up of Patients 
1:1 Matched on Propensity Scores. (n=578) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -6.4208 1.2787 -8.9271 -3.9145 25.21 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.1890 0.2101 -0.2227 0.6008 0.81 0.3683 
age 1 0.0343 0.0238 -0.0124 0.0810 2.07 0.1503 
sex 1 0.7050 0.2313 0.2516 1.1585 9.29 0.0023 
Healthcare plan 
(FFS only vs. HMO 
involved) 
1 0.5266 0.2424 0.0516 1.0016 4.72 0.0298 
Heavy smoking 
(Yes/No) 
1 1.3052 0.2436 0.8278 1.7827 28.71 <.0001 
Heart failure 
(Yes/No) 
1 0.8126 0.2523 0.3182 1.3070 10.38 0.0013 
Anxiety and 
depression (Yes/No) 
1 0.3772 0.2306 -0.0748 0.8293 2.68 0.1019 
No. of 
COPD-related ED 
visits in previous 
year 
1 0.4782 0.1986 0.0888 0.8675 5.79 0.0161 





Table 41. Negative Binomial Regression on Number of All-cause Hospitalizations 
and Emergency Department Visits during Follow-up of 1:1 Matched Patients on 
Propensity Scores. 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -1.7047 0.8675 -3.4049 -0.0045 3.86 0.0494 
Levalbuterol (1) or 
albuterol (0) 
1 -0.0648 0.1557 -0.3699 0.2404 0.17 0.6775 
age 1 -0.0148 0.0161 -0.0463 0.0167 0.85 0.3579 
sex 1 0.2567 0.1679 -0.0723 0.5857 2.34 0.1262 
Heavy smoking 
(Yes/No) 
1 0.9606 0.1723 0.6229 1.2984 31.07 <.0001 
Heart failure 
(Yes/No) 
1 0.7236 0.1952 0.3411 1.1061 13.75 0.0002 
Hypertension 
(Yes/No) 




1 -0.6112 0.2299 -1.0619 -0.1606 7.07 0.0079 
hyperlipidemia 
(Yes/No) 
1 0.5445 0.1776 0.1964 0.8926 9.40 0.0022 
Methylxanthine use 
in previous year 
(Y/N) 
1 -0.8554 0.3911 -1.6218 -0.0889 4.78 0.0287 





Regression on all eligible patients instead of on PSM matched patients 
When using all the eligible patients for the negative binomial regression, there 
was no statistically significant difference in the number of COPD-related and all-cause 
hospitalizations and ED visits between albuterol and levalbuterol (Table 42 and Table 
43). 
 
Table 42. Negative Binomial Regression of Number of COPD-Related 
Hospitalizations and Emergency Department Visits on All Eligible Patients. 
(n=4597) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -7.3139 0.5396 -8.3715 -6.2564 183.73 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.2778 0.1695 -0.0545 0.6101 2.68 0.1013 
age 1 0.0717 0.0093 0.0535 0.0900 59.30 <.0001 
sex 1 0.4098 0.0941 0.2253 0.5943 18.96 <.0001 
Race and ethnic group 
(White vs. non-White) 
1 -0.4788 0.0950 -0.6650 -0.2926 25.40 <.0001 
Healthcare plan (FFS 
only vs. HMO involved) 
1 0.1573 0.0979 -0.0345 0.3492 2.58 0.1080 
Preexisting or newly 
diagnosed COPD 
1 -0.5403 0.1175 -0.7705 -0.3101 21.17 <.0001 
Heavy smoking 
(Yes/No) 
1 1.1229 0.0997 0.9276 1.3183 126.98 <.0001 
Heart failure (Yes/No) 1 0.7364 0.1310 0.4797 0.9932 31.61 <.0001 
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Chi-Square Pr > ChiSq 
Cardiac arrhythmia 
(Yes/No) 
1 0.3000 0.1559 -0.0056 0.6055 3.70 0.0543 




1 -0.2415 0.1480 -0.5316 0.0487 2.66 0.1029 
Asthma ever diagnosed 
(Yes/No) 
1 -0.2435 0.0935 -0.4267 -0.0602 6.78 0.0092 
No. of hospitalizations 
in previous year 
1 0.3482 0.0719 0.2073 0.4892 23.45 <.0001 
No. of emergency 
department (ED) visits 
in previous year 
1 0.0462 0.0231 0.0010 0.0915 4.01 0.0453 
No. of COPD-related 
ED visits in previous 
year 
1 0.5058 0.0893 0.3308 0.6808 32.11 <.0001 
copd_prev1yrphys_cnt 1 0.1269 0.0498 0.0293 0.2245 6.50 0.0108 
No. of COPD-related 
physician office visits in 
previous year 
1 0.0689 0.0235 0.0230 0.1149 8.64 0.0033 
No. of non-COPD 
prescriptions in 
previous year 
1 -0.0042 0.0017 -0.0075 -0.0009 6.09 0.0136 
LABA-ICS 
combination use in 
previous year (Y/N) 
1 -0.5839 0.1916 -0.9595 -0.2083 9.29 0.0023 
LTRA use in previous 
year (Y/N) 
1 -0.5981 0.2560 -1.0999 -0.0963 5.46 0.0195 
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Chi-Square Pr > ChiSq 
ICS use in previous 
year (Y/N) 
1 -1.3359 0.2543 -1.8342 -0.8375 27.60 <.0001 
Dispersion 1 5.4473 0.1405 5.1720 5.7227   
 
Table 43. Negative Binomial Regression of Number of All-Cause Hospitalizations 
and Emergency Department Visits on All Eligible Patients. (n=4597) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -4.2842 0.3333 -4.9373 -3.6310 165.27 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.0100 0.1202 -0.2255 0.2456 0.01 0.9335 
age 1 0.0371 0.0061 0.0252 0.0490 37.60 <.0001 
sex 1 0.2003 0.0630 0.0768 0.3238 10.10 0.0015 
Race and ethnic 
group (White vs. 
non-White) 
1 0.0822 0.0612 -0.0378 0.2022 1.80 0.1794 
Healthcare plan 
(FFS only vs. HMO 
involved) 
1 0.1929 0.0640 0.0675 0.3183 9.09 0.0026 
Heavy smoking 
(Yes/No) 
1 0.6319 0.0645 0.5054 0.7584 95.85 <.0001 
Heart failure 
(Yes/No) 
1 0.4834 0.0882 0.3105 0.6563 30.03 <.0001 
Diabetes mellitus 
(Yes/No) 
1 0.1345 0.0709 -0.0045 0.2735 3.60 0.0578 
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1 0.3018 0.0498 0.2043 0.3994 36.77 <.0001 
No. of emergency 
department (ED) 
visits in previous 
year 
1 0.1177 0.0172 0.0840 0.1514 46.88 <.0001 
No. of outpatient 
services in previous 
year 
1 0.0406 0.0104 0.0202 0.0611 15.17 <.0001 
No. of COPD-related 
ED visits in previous 
year 
1 0.1597 0.0616 0.0389 0.2805 6.71 0.0096 
No. of non-COPD 
prescriptions in 
previous year 
1 -0.0041 0.0012 -0.0064 -0.0018 12.26 0.0005 
Other SABA use in 
previous year (Y/N) 
1 -1.0077 0.4425 -1.8750 -0.1403 5.19 0.0228 
LABA use in 
previous year (Y/N) 
1 -0.6183 0.2110 -1.0318 -0.2048 8.59 0.0034 
LABA-ICS 
combination use in 
previous year (Y/N) 
1 -0.2650 0.1194 -0.4991 -0.0309 4.92 0.0265 
LTRA use in 
previous year (Y/N) 
1 -0.4117 0.1646 -0.7342 -0.0892 6.26 0.0124 
ICS use in previous 
year (Y/N) 
1 -0.8004 0.1750 -1.1435 -0.4574 20.91 <.0001 




Using COPD-related all healthcare resources utilization as outcome measure 
When using number of COPD-related all healthcare resources utilization as 
outcome measure, albuterol/levalbuterol (0/1) was a significant predicator. Comparing to 
COPD-related hospitalizations and ED visit, this might imply that number of outpatient 
services and physician office visits increased more among levalbuterol users than in 
albuterol users. Other important predictors included diabetes (yes/no), healthcare plan, 
heart failure, heavy smoking, number of COPD-related physician office visits in previous 
year, race and ethnic group, and sex. These factors had significant impact on the number 
of COPD-related all health services utilization in all the following three analyses. 
 
Table 44. Negative Binomial Regression on Number of COPD-related All Health 
Services Utilization during Follow-up of Patients 1:5 Matched on Propensity 
Scores.* (n=1722) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -4.1313 0.6117 -5.3302 -2.9325 45.62 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.2982 0.1356 0.0323 0.5640 4.83 0.0279 
age 1 0.0396 0.0106 0.0188 0.0605 13.86 0.0002 
sex 1 0.5074 0.1101 0.2917 0.7232 21.25 <.0001 
Race and ethnic 
group (White vs. 
non-White) 
1 -0.3859 0.1153 -0.6119 -0.1599 11.20 0.0008 
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Chi-Square Pr > ChiSq 
Healthcare plan (FFS 
only vs. HMO 
involved) 
1 0.3941 0.1191 0.1607 0.6275 10.95 0.0009 
Preexisting (0) or 
newly diagnosed 
COPD (1) 
1 -0.7043 0.1356 -0.9701 -0.4386 26.98 <.0001 
Heavy smoking 
(Yes/No) 
1 0.7545 0.1135 0.5320 0.9771 44.17 <.0001 
Heart failure 
(Yes/No) 
1 0.5112 0.1388 0.2392 0.7833 13.56 0.0002 
Hypertension 
(Yes/No) 




1 -0.4547 0.1641 -0.7764 -0.1330 7.68 0.0056 
Diabetes mellitus 
(Yes/No) 
1 -0.3475 0.1277 -0.5978 -0.0973 7.41 0.0065 
Hyperlipidemia 
(Yes/No) 
1 0.3723 0.1390 0.0999 0.6447 7.17 0.0074 
No. of outpatient 
services in previous 
year 
1 0.0718 0.0170 0.0386 0.1051 17.91 <.0001 
No. of COPD-related 
ED visits in previous 
year 
1 0.3614 0.0948 0.1756 0.5471 14.53 0.0001 
No. of COPD-related 
physician office visits 
in previous year 
1 0.2791 0.0504 0.1803 0.3780 30.63 <.0001 
No. of non-COPD 
prescriptions in 
previous year 
1 -0.0105 0.0022 -0.0148 -0.0063 23.47 <.0001 
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Chi-Square Pr > ChiSq 
Other SABA use in 
previous year (Y/N) 
1 -1.7262 0.5574 -2.8185 -0.6338 9.59 0.0020 
LABA use in 
previous year (Y/N) 
1 -0.8445 0.3192 -1.4702 -0.2188 7.00 0.0082 
Dispersion 1 3.5328 0.1161 3.3053 3.7604   
 
Table 45. Negative Binomial Regression on Number of COPD-related All Health 
Services Utilization during Follow-up of Patients 1:1 Matched on Propensity 
Scores.* (n=578) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -3.7415 0.9840 -5.6700 -1.8130 14.46 0.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.3437 0.1659 0.0186 0.6688 4.29 0.0382 
age 1 0.0164 0.0179 -0.0187 0.0516 0.84 0.3593 
sex 1 0.4825 0.1827 0.1244 0.8405 6.97 0.0083 
Race and ethnic 
group (White vs. 
non-White) 
1 -0.6112 0.2068 -1.0164 -0.2059 8.74 0.0031 
Healthcare plan (FFS 
only vs. HMO 
involved) 
1 0.6017 0.1927 0.2241 0.9794 9.75 0.0018 
Heavy smoking 
(Yes/No) 
1 0.6382 0.1882 0.2693 1.0071 11.50 0.0007 
Heart failure 
(Yes/No) 
1 0.5573 0.2172 0.1316 0.9831 6.58 0.0103 
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Analysis Of Maximum Likelihood Parameter Estimates 











1 -0.5531 0.2484 -1.0400 -0.0662 4.96 0.0260 
Lung cancer (Yes/No) 1 1.2944 0.6207 0.0778 2.5110 4.35 0.0370 
Diabetes mellitus 
(Yes/No) 
1 -0.5422 0.1978 -0.9299 -0.1545 7.51 0.0061 
hyperlipidemia 
(Yes/No) 
1 0.7583 0.1914 0.3833 1.1334 15.70 <.0001 
No. of outpatient 
services in previous 
year 
1 -0.3020 0.1415 -0.5793 -0.0248 4.56 0.0327 
No. of COPD-related 
hospitalizations in 
previous year 
1 0.7639 0.2400 0.2936 1.2342 10.13 0.0015 
No. of COPD-related 
ED visits in previous 
year 
1 0.2192 0.1378 -0.0508 0.4893 2.53 0.1116 
No. of COPD-related 
physician office visits 
in previous year 
1 0.2988 0.0759 0.1500 0.4475 15.50 <.0001 
Other SABA use in 
previous year (Y/N) 
1 -2.0326 1.2376 -4.4582 0.3930 2.70 0.1005 
Methylxanthine use 
in previous year 
(Y/N) 
1 -0.6669 0.4438 -1.5367 0.2029 2.26 0.1329 




Table 46. Negative Binomial Regression on Number of COPD-related All Health 
Services Utilization during Follow-up of All Eligible Patients.* (n=4597) 
Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Intercept 1 -5.0028 0.3999 -5.7865 -4.2191 156.53 <.0001 
Levalbuterol (1) or 
albuterol (0) 
1 0.2846 0.1298 0.0302 0.5390 4.81 0.0283 
age 1 0.0533 0.0069 0.0397 0.0669 58.91 <.0001 
Sex (female 0) 1 0.2705 0.0718 0.1297 0.4113 14.18 0.0002 
Race and ethnic 
group (White vs. 
non-White) 
1 -0.5134 0.0721 -0.6547 -0.3720 50.66 <.0001 
Healthcare plan (FFS 
only vs. HMO 
involved) 
1 0.4197 0.0734 0.2757 0.5636 32.66 <.0001 
Preexisting or newly 
diagnosed COPD 
1 -0.5312 0.0897 -0.7071 -0.3554 35.05 <.0001 
Heavy smoking 
(Yes/No) 
1 0.7751 0.0728 0.6325 0.9177 113.48 <.0001 
Ischemic heart 
disease (Yes/No) 
1 0.2120 0.0959 0.0240 0.4000 4.89 0.0271 
Heart failure 
(Yes/No) 
1 0.4181 0.1031 0.2160 0.6202 16.44 <.0001 
Hypertension 
(Yes/No) 




1 -0.1708 0.1102 -0.3867 0.0452 2.40 0.1211 
Lung cancer (Yes/No) 1 0.7733 0.2345 0.3138 1.2329 10.88 0.0010 
Diabetes mellitus 
(Yes/No) 
1 -0.1927 0.0828 -0.3551 -0.0303 5.41 0.0200 
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Analysis Of Maximum Likelihood Parameter Estimates 







Chi-Square Pr > ChiSq 
Asthma ever 
diagnosed (Yes/No) 




1 0.2072 0.0543 0.1007 0.3136 14.55 0.0001 
No. of COPD-related 
ED visits in previous 
year 
1 0.3545 0.0633 0.2304 0.4786 31.35 <.0001 
No. of COPD-related 
outpatient services in 
previous year 
1 0.2526 0.0678 0.1196 0.3855 13.86 0.0002 
No. of COPD-related 
physician office visits 
in previous year 
1 0.4040 0.0403 0.3250 0.4831 100.32 <.0001 
No. of non-COPD 
prescriptions in 
previous year 
1 -0.0060 0.0013 -0.0086 -0.0035 21.11 <.0001 
ICS use in previous 
year (Y/N) 
1 -0.8674 0.1865 -1.2329 -0.5018 21.63 <.0001 





Using propensity score matching, this study found there were no differences in 
all-cause hospitalizations and emergency department visits and in COPD-related 
hospitalizations and emergency department visits between patients taking albuterol and 
levalbuterol. However, there was significant difference in COPD-related all healthcare 
resources utilization. This might imply COPD patients used more outpatient services and 
physician office visits than inpatient services and ED visits; and levalbuterol users had 
more such ambulatory care visits than albuterol users. 
From the study results, it is safer to conclude that there was no significant 
difference between albuterol and levalbuterol in terms of health services utilization. And 
in practice levalbuterol users had more COPD-related all healthcare resource utilization 
than albuterol users. 
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Study Objective 3: Cost-Consequence Analysis of Albuterol and Levalbuterol in 
South Carolina Medicaid Programs 
Descriptive Statistics of Costs before and after Albuterol and Levalbuterol 
Treatment 
Table 47 shows the overall costs of health services and medications 1 year before 
and 1 year after prescription index dates in 578 patients 1:1 matched on propensity scores. 
The average of all costs of health services and medications increased in the following 
year after initiation of albuterol or levalbuterol [$10,641 (±17,823) pre-index vs. $17,672 
(±24,973) post-index]. Costs of health services overwhelmed medication costs. COPD 
related costs were dominated by non-COPD related costs, as for both health services and 
medications. This may imply that comorbidities or coexisting medical conditions in 




Table 47. Costs of Health Services and Medications Before and After Albuterol or Levalbuterol Use. 
  
1 year pre-index (n=578) 1 year post-index (n=578) 
  Mean SD Median IQR Mean SD Median IQR 
All costs (health service costs + medication costs) 10641.5 17823.9 4206.1 11242.6 17672.6 24973.4 9742.8 16521.9 
Overall health service costs  8546.1 16835.3 1973.4 8197 12759.6 23874.3 4503.4 13265.3 
COPD related  2475.5 7607.3 59.6 907.5 3746.6 11299.3 168.5 1658.4 
 Total inpatient services costs 1805.2 7133.3 0 0 2096.6 9084.2 0 0 
 Total emergency-department visit costs 381.5 1603.5 0 0 992.4 4027.1 0 0 
 Total outpatient service costs 54.2 233.8 0 0 78.4 355.2 0 0 
 Total physician-office visit costs 33.3 93.2 0 0 74.5 163.9 0 82.4 
 Total other ambulatory care costs 201.3 784.7 0 75.2 504.7 2309.5 3.9 225.7 
Non-COPD related  6070.5 14242.4 1154.7 4905.4 9013.0 19001.8 2972.5 8912 
 Total inpatient services costs 453.8 1973.2 0 119.6 666.3 2390.6 0 186.4 
 Total emergency-department visit costs 2242.1 10371.5 0 0 2625.1 11738.8 0 0 
 Total outpatient service costs 381.8 1196.1 0 260.5 716.6 2301.2 158.6 651.5 
 Total physician-office visit costs 565.5 2321.4 90.9 472.9 1170.2 6108.3 381.4 932.5 
 Total other ambulatory care costs 2427.4 6086.3 427.2 2010.6 3834.9 7754.3 1293.9 3728.7 
Overall medication costs  2095.4 3728.1 662.4 2658.7 4913.0 5162.9 3606.9 4565.3 
 Albuterol  0 0 0 0 172.1 323.4 52.9 160.4 
 Levalbuterol  0 0 0 0 167.1 501.4 0 116.4 
 Other COPD drugs 107.7 337.1 0 8.3 438.2 806.4 77.9 515 




With regard to the pre-post differences between albuterol and levalbuterol 
(difference in difference), as shown in Table 48, there were no differences in overall 
costs (health services plus medications), health service costs (COPD-related + 
non-COPD-related), non-COPD related health service costs, or non-COPD drugs. But 
there were significant differences in COPD-related health service costs, total drug costs, 
as well as COPD drug costs including albuterol and levalbuterol. All the costs with 
significant differences were higher in levalbuterol group than in albuterol group. 
Interestingly, the COPD-related health service costs in patients who used 
albuterol in the following year decreased than in the year before albuterol initiation. 
To explain the study findings above, we might infer that when a COPD patient 
had a likely equal probability (determined by propensity score matching) to receive either 
albuterol or levalbuterol, levalbuterol did not show economic dominance over albuterol 
in terms of the costs (measured by SC Medicaid payment) in the following year. 
Table 49 shows the results of DID regression analysis which took the group and 
time into consideration, after excluding those independent variables whose p < 0.1 in the 
previous modeling. It shows that levalbuterol use (vs. albuterol), number of 
COPD-related hospitalizations in previous year, and heavy smoking were significant 
factors for COPD-related healthcare costs. After controlling for other factors, 
COPD-related health service costs in albuterol users were $2776 less than levalbuterol 
users. 
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Table 48. Costs of Health Services and Medications Before and After Albuterol or Levalbuterol Use, by Albuterol and Levalbuterol Groups. 










 P value of DID 
analysis 
 Mean SD Mean SD 
Average 
Difference 
Mean SD Mean SD 
Average 
Difference 
All costs (health services + 
drugs) 
9724.1 16304.2 15897.9 26355.6 6173.8 11558.9 19208.5 19447.3 23421.6 7888.4 .4023 
Overall health service costs 7657.4 15450.0 11498.3 25343.1 3840.9 9434.7 18098.3 14020.9 22281.8 4586.2 .7075 
COPD related health service 
costs 
2255.0 7395.4 2080.9 6605.4 −174.0 2696.1 7819.9 5412.2 14373.3 2716.1 .0055 
Total inpatient services costs 1613.1 6744.8 1175.3 5638  1997.4 7508.5 3017.9 11482.2   
Total emergency-department 
visit costs 
345.2 1518.9 525.8 2435  417.7 1685.7 1459 5111.3  
 
Total outpatient service costs 55 219.6 65.2 391.6  53.5 247.6 91.7 314.6   
Total physician-office visit 
costs 
36.2 102.2 56.8 151.9  30.5 83.3 92.1 173.5  
 
Total other ambulatory care 
costs 
205.5 924.6 257.8 838.7 
 
197.1 615.4 751.5 3140.2 
  
Non-COPD related health 
service costs 
5402.4 12066.4 9417.4 22683.6 4014.9 6738.6 16121.4 8608.7 14440.3 1870.1 .1761 
Total inpatient services costs 482.8 2066.6 633 2384.2  424.7 1878.3 699.5 2400.7   
Total emergency-department 
visit costs 
1744.9 7893.3 3351.2 14443.9  2739.3 12357.5 1898.9 8148.3  
 
Total outpatient service costs 402.3 1084.8 670.7 2795.9  361.3 1299.4 762.4 1669.7   
Total physician-office visit 
costs 
717.5 3179.9 1547.9 8535.6 
 
413.4 798.8 792.5 1269.3 
  
Total other ambulatory care 
costs 
2055 4689.1 3214.6 6141 
 
2799.8 7207.5 4455.3 9054.4 
  
Overall medication costs 2066.7 3528.1 4399.6 5345 2332.9 2124.1 3923.9 5426.4 4930.1 3302.3 .0082 
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 P value of DID 
analysis 
 Mean SD Mean SD 
Average 
Difference 
Mean SD Mean SD 
Average 
Difference 
Albuterol 0 0 120.2 190.1 120.2 0 0 224.0 409.9 224.0 .0001 
Levalbuterol 0 0 8.4 111 8.4 0 0 325.9 663.9 325.9 < .0001 
Other COPD drugs 110.5 314.5 376.9 727.4 266.4 104.9 358.7 499.5 875.3 394.6 .0310 
Non-COPD drugs 1956.2 3414.2 3894 5147.9 1937.9 2019.3 3875.9 4377.0 4642.0 2357.7 .2175 
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Table 49. Difference-in-Difference Regression on COPD-Related Health Service Costs Before and After Albuterol or 
Levalbuterol Use. 
Solution for Fixed Effects 
Effect leval_flag sex race_ethn plan pre_new smkg Estimate 
Standard 
Error DF t Value 
Pr > 
|t| 
Intercept       -2563.17 6093.14 569 -0.42 0.6742 
Albuterol (leval_flag=0) 0      -2775.62 1015.44 569 -2.73 0.0065 
Levalbuterol (leval_flag=1) 1      0 . . . . 
age       160.81 112.48 569 1.43 0.1534 
Female (Sex=0)  0     -1855.15 1081.06 569 -1.72 0.0867 
Male (sex=1)  1     0 . . . . 
White (race_ethn=0)   0    -341.21 1194.14 569 -0.29 0.7752 
Non-White (race_ethn=1)   1    0 . . . . 
Healthcare plan, FFS only    0   -370.76 1173.07 569 -0.32 0.7521 
Healthcare plan, HMO involved    1   0 . . . . 
Preexisting COPD (pre_new=0)     0  1466.12 1278.44 569 1.15 0.2519 
Newly diagnosed COPD (pre_new=1)     1  0 . . . . 
Without heavy smoking (smkg=0)      0 -2938.12 1100.89 569 -2.67 0.0078 
heavy smoking (smkg=1)      1 0 . . . . 
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Solution for Fixed Effects 
Effect leval_flag sex race_ethn plan pre_new smkg Estimate 
Standard 
Error DF t Value 
Pr > 
|t| 
No. of COPD-related hospitalizations in 
previous year 





Cost-Consequence Analysis of Albuterol and Levalbuterol Nebulizers 
The average payment for albuterol nebulizer was $35.6 (±$33.7) per prescription 
(median and IQR, $25.2 and $35.6), while for levalbuterol $203.5 (±$122.9) (median and 
IQR, $181.6 and $199.2). 
Figure 6 shows the patient selection flow for the cost-consequence analysis of 
albuterol and levalbuterol. Due to the small sample size of levalbuterol HFA group (n=17) 
and patients who used both levalbuterol HFA inhaler and levalbuterol nebulizer (n=7), 
only patients who used albuterol or levalbuterol inhalation solution (nebulizer) were 
included for economic evaluation here. 
Table 50 shows the descriptive statistics of all types of direct medical costs 
between racemic albuterol and levalbuterol users. There was no difference (p = .7431 for 
DID) in the increase of all cost ($7472 increase in albuterol group vs. $6478 increase in 
levalbuterol group) between these two groups. There were no differences in all the 
subcategories of medical costs (such as health service cost and medication cost). 
 
Summary 
When not differentiating the various dosage forms (i.e., aerosol inhaler/MDI, 
inhalation solution/nebulizer, orally administered such as tablet and syrup) of albuterol 
and levalbuterol, the cost-consequence analysis showed levalbuterol did not have 
economic advantage over albuterol in terms of the costs (measured by SC Medicaid 
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payment) in the following year. While comparing nebulizers of albuterol and levalbuterol, 
there were no differences in all the medical cost subcategories, implying that albuterol 






4597 patients who met inclusion criteria of study objective 2 
2315 patients who used albuterol HFA 
products or albuterol nebulizer 
416 patients who used both 
albuterol and levalbuterol excluded 
99 patients who used levalbuterol HFA 
products or levalbuterol nebulizer 
17 used levalbuterol HFA 
75 used levalbuterol nebulizer 
7 used both forms 
1063 used albuterol HFA 
782 used albuterol nebulizer 
470 used both forms 
1767 patients who used other forms of 
albuterol 
Figure 6. Selection Flow of Patients Who Used Albuterol or Levalbuterol for 
Economic Evaluation. 
Only nebulizer (inhalation solution) compared between albuterol 
(n=782) and levalbuterol (n=75) 
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Table 50. Costs of Health Services and Medications Before and After Use of Albuterol or Levalbuterol Nebulizer. 
  Albuterol Solution (n=782) Levalbuterol Solution (n=75) Difference of 
differences 























All costs (health services + drugs) 9831.9 17303.8 7471.9 13247.3 19725.6 6478.3 993.58 .7431 
Overall health service costs 7993.9 13020.4 5026.4 11029.9 14320.9 3291 1735.43 .5516 
COPD related health service costs 2464.7 3139.2 674.4 2423.9 2688 264 410.40 .8108 
 
Total inpatient services 
costs 





429.6 791.2  229.2 699.3   
 
 
Total outpatient service 
costs 





29.4 53.6  29 80.8   
 
 
Total other ambulatory 
care costs 
159.3 520.4  166.3 432.4   
 
Non-COPD related health service costs 5529.2 9881.2 4352 8606 11633 3027 1325.03 .5463 
 
Total inpatient services 
costs 






579.9 903.2  208.5 418.7   
 
 
Total outpatient service 
costs 





548.2 1257.8  425 819.4   
 
 Total other ambulatory 2379.5 5024.7  4474.3 6242.8    
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  Albuterol Solution (n=782) Levalbuterol Solution (n=75) Difference of 
differences 



























 1837.9 4283.4 2445.5 2217.4 5404.7 3187.3 −741.85 .1441 
 Albuterol nebulizer 0 144.5 144.5 0 49.3 49.3 95.20 .0007 
 Levalbuterol nebulizer 0 0 0 0 598.1 598.1 −598.14 < .0001 
 Other COPD drugs 83.5 371.8 288.4 77.9 425.9 348.0 −59.67 .4147 




CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 
This dissertation research is an observational, longitudinal, population-based 
study of initial use of albuterol and levalbuterol by chronic obstructive pulmonary 
disease (COPD) patients using the South Carolina Medicaid claims databases. Patients 
who were initially prescribed albuterol seemed to have no differences in health service 
utilization and healthcare cost in the following year comparing to those prescribed 
levalbuterol. Thus, the study findings suggest that albuterol may be equally or similarly 
effective comparing with levalbuterol in the first year of their use in terms of utilization 
of hospitalizations and emergency department visits. 
COPD placed a heavy economic burden on the South Carolina Medicaid 
programs, as this study showed. In the era of healthcare cost containing and comparative 
effectiveness research, it is required to act on CER in and economic evaluation of COPD 
to find better alternatives .17 In the pharmaceutical industry and pharmacy-research 
community, relatively newer drugs are usually of special interests (e.g., long-acting 
anticholinergics and long-acting β-agonists in COPD5 and ranibizumab [Lucentis] and 
bevacizumab [Avastin] for neovascular age-related macular degeneration67-69). But it 
does not mean older regimens are not important for study. Albuterol and levalbuterol are 
exactly such examples for CER and economic evaluation. As presented in Chapters 1 and 
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2, a couple of small RCTs10,13,14 as well as one (1) chart review study15 that compared 
albuterol and levalbuterol have yielded conflicting results. Furthermore, the sample size 
of the studies (30,13 241 hospitalized patients with acute asthma or COPD using 
levalbuterol and 238 using racemic albuterol,10 125 patients with COPD or asthma in 
nebulized racemic albuterol group and 109 patients in levalbuterol15) was small and 
follow-up length was short (2 weeks10 and 6 weeks14). And thus more evidence of the 
comparative clinical effectiveness and economic outcomes between albuterol and 
levalbuterol is needed. In addition to the strengths of observational studies comparing to 
RCTs,5,38 this study followed more patients (n=289 using levalbuterol and more on 
albuterol) for 1 year after prescription index date, which is another important strength. 
This study, however, did not show the advantages of levalbuterol compared with 
racemic albuterol in terms of health service utilization and healthcare cost (i.e., the SC 
Medicaid payment). On the contrary, a sensitivity analysis indicated that levalbuterol 
users had 34% more COPD-related healthcare resource utilization. And COPD-related 
health service costs were higher in levalbuterol patients than in racemic albuterol users. 
However, when comparing nebulized albuterol and levalbuterol, there was no difference 
in incremental cost. This study was not designed to determine the underlying reasons. 
But a possibility is that the sample size of nebulizers (Table 50) decreased comparing 




This study has limitations. First, SC Medicaid claims database is a convenience 
sample. The data are not reflective of either the entire U.S. or South Carolina population. 
The databases include only individuals with Medicaid; do not include people with private 
insurance and Medicare as well as the uninsured and cash payers. People who might have 
other coverage included those dual-eligible beneficiaries of Medicare and Medicaid 
(excluded from study Objectives 2 & 3) and those who were medically complex. But the 
enrollees were more than likely uncovered by any other insurance besides Medicaid 
during enrollment (personal communication with the ORS, SC Department of Health & 
Human Services). In this regard, the most serious limitation is that we cannot compare 
albuterol and levalbuterol in older patients (≥ 65 years of age) with COPD, who are more 
vulnerable by this disease. If future study would like to focus on this subpopulation, 
other appropriate databases (such as Medicare database) are required. 
Second, health service claims include information on diagnosed conditions and 
services performed while undiagnosed conditions were not captured. And sometimes the 
coded diagnosis might be resulting from misclassification error.5 In addition, lifestyle and 
biometric factors (such as smoking status and BMI) were not well-captured in claims. 
The laboratory results (such as lung function) were not found in claims either. Such data 
unavailability could limit the inclusion of useful variables for analysis and lead to 
selection bias or potential confounding. However, the confounding was less likely to 
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occur because this study controlled for many prognostically important variables and used 




Except those mentioned above in Study Limitations, future research may be 
focused on per protocol effect (or time-on-treatment analysis), in addition to 
intention-to-treat analysis used in this study. More importantly, mortality can be used as a 
primary end point to compare the effectiveness of racemic albuterol and levalbuterol. 
Except the comparison of nebulizers (or inhalation solution) of racemic albuterol 
and levalbuterol, an economic evaluation of HFA-containing metered dose inhalers 
between albuterol and levalbuterol is also needed. 
 
Conclusions 
Specific conclusions are as follows: 
1. COPD placed a heavy economic burden on the healthcare systems and 
Medicaid programs of South Carolina. 
2. There was significant difference in number of COPD-related health services 
utilization between racemic albuterol and levalbuterol users; but there was no 
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difference in number of COPD-related or all-cause hospitalizations and ED 
visits between these two cohorts. 
3. While comparing just nebulizers of albuterol and levalbuterol, there were no 
differences in all the direct medical costs and their subcategories (i.e., health 
services costs and medication costs) in the following year from the SC 
Medicaid perspective. 
In summary, the dissertation project conducted a population-based, retrospective, 
observational study of new use of levalbuterol and racemic albuterol in COPD patients 
who were older than 45 and younger than 65 years of age using South Carolina Medicaid 
claims databases. The study found that patients initially prescribed levalbuterol seemed 
to have no difference in health service utilization and healthcare cost in the following one 
year comparing with racemic albuterol. This suggests that racemic albuterol might be 
equally or similarly effective initial therapy for patients with COPD comparing with 
levalbuterol. Future research is needed to examine the longer-term comparative 
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